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1. Introduction  
1.1 Melanoma 
Melanoma, also known as cutaneous melanoma or malignant melanoma is the 
malignancy of melanocytes. It is one of the most aggressive forms of skin cancer. It 
accounts for only 4% of all skin cancers but is responsible for more than 75% of 
deaths due to skin cancers (Arrangoiz et al., 2016). A world-wide increase in 
melanoma incidence has been observed among the caucasian population. Australia 
has the maximum rate of incidence with 50-60 new cases per 100,000 populations, 
which is followed by United States of America (USA) and Europe with 20-30 and 10-
25 new cases per 100,000 populations respectively (Garbe et al., 2016).  
1.1.1 Melanoma subtypes 
Classically or histologically melanoma has been grouped into four subtypes: 
Superficial spreading melanoma is the most common subtype and accounts for 
approximately 70% of all melanoma cases in the white population. It is irregular in 
shape and spread alongside epidermis. Nodular melanoma is another common 
subtype where the melanocytes grow vertically rather that spreading horizontally. 
The borders of nodular melanoma are more distinct compared to superficial 
melanoma. The third subtype of melanoma is lentigo malignant melanoma, which 
is frequently developed on sun-exposed part of skin like forearms, face and neck of 
elderly people. It can also invade through the dermis. Acral lentiginous melanoma 
is the fourth subtype of melanoma which is least common in Caucasian but usually 
found in people with other race for e.g. African-American or Asian. Mostly, it occurs 
in palm, sole or under nails (Smoller, 2006). 
1.1.2 Melanoma and Risk factors 
Transformation of melanocytes to melanoma could arise due to several factors like 
sun exposure, family history or immunosuppression. However, exposure to the sun 
or ultra violet (UV) radiation has been accounted as the major cause of melanoma 
(Gandini et al., 2005). 
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UV exposure can cause increased production of growth factors and reactive oxygen 
species which further leads to DNA damage and genetic alterations (Huang et al., 
1996). However, melanin, pigments present in human skin, absorbs and dissipates 
UV light and protects the skin from any DNA damage. Melanin is produced by 
melanocytes and transported to the keratinocytes so that they are similarly 
distributed in the skin (Brenner and Hearing, 2008). 
People with a large number of congenital melanocytic nevi are at higher risk of 
developing melanoma. The reports also suggest that chances of developing 
melanoma from congenital melanocytic nevi are between 20-30% (Ribeiro et al., 
2016). Although melanoma can arise from the pre-existing nevus, approximately 
75% of the melanoma occurs de novo. Nonetheless, these nevi can be surgically 
removed to reduce the risk. 
Melanoma is an immunogenic tumour and some studies have found that the risk of 
developing melanoma increases by 20-60 times in immunosuppressed people than 
normal population (Moloney et al., 2006). It is more common in 
immunocompromised people with solid organ transplant recipients (OTRs), patients 
with human immunodeficiency virus (HIV) infection/AIDS. (Kubicaa and Brewer, 
2012).  
Another strong risk factor for melanoma is the family history. Around 10% of the 
melanoma patients have some close family members already diagnosed with 
melanoma. To date, two genes, cyclin-dependent kinase inhibitor 2A (CDKN2A) and 
cyclin-dependent kinase 4 (CDK4) are implicated in familial melanoma. Besides, 
CDKN2A is found to be mutated in 20-40% of members of familial melanoma (Read 
et al., 2016). 
 
1.2 Melanocyte to melanoma 
1.2.1 Melanocyte development 
Melanoma cells exploit the normal developmental process of melanocyte for its 
progression. But the exact mechanism behind this is not clearly understood.  In the 
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process to illuminate this association, it is important to understand the developmental 
process of melanocytes. 
Melanocytes are a group of special heterogeneous cells which originates from 
embryonic neural crest (NC) cells. Development of melanocytes encompasses 
several complex phases. It starts with lineage specification from neural crest cells 
and forms melanoblast precursors. Melanoblasts then mature, proliferate and 
migrate to the epidermis. Here they are incorporated into hair follicles and further 
differentiates to melanocytes. Eventually, melanocytes produce melanin in special 
organelles known as melanosomes (O'Rahilly and Müller, 2007) (Ernfors, 2010). In 
human, melanosomes are transported to keratinocytes as a defensive measure to 
protect from DNA damage of skin due to sun or UV exposure. Melanin absorbs and 
dissipates UV light energy (Gilchrest and Eller, 1999).  
1.2.1.1 Pathways and genetics of melanocyte development 
As I mentioned earlier that melanocytes are differentiated from highly migratory 
neural crest cells and during this differentiation several signalling pathways are 
activated. For example, BMP signalling is important for the early neural crest 
induction. Kanzler et al in 2000 demonstrated that knocking down BMP2 in mouse 
leads to the loss of neural crest derivatives. Later, the role of snail/slug family is 
crucial as it helps during the epithelial to mesenchymal transition (EMT) of neural 
crest progenitor cells. Snail/slug directly represses E-cadherin and blocks cell 
adhesion which ultimately allows cell migration (Cano et al., 2000). Multiple roles of 
Notch family have been recognised during neural crest cell differentiation. In mouse, 
loss or gain of notch signalling could affect the neural crest cell migration, 
proliferation, differentiation and fate decision of early progenitors (Mead and Yutzey, 
2012). Another study found that notch signalling plays the determining role in 
melanoblasts and adult melanocyte stem cells survival (Moriyama et al., 2006). 
Melanoblast formation is one more essential stage during melanocyte development. 
Study using Wnt-1 and Wnt-3a knock-out mouse suggested reduction in neural crest 
derivative thus deciding the fate of melanocyte maturation (Ikeya et al., 1997). Later, 
a fate mapping study showed that Wnt signalling is also critical in melanocyte 
formation by blocking glial and neuronal fates (Dorsky et al., 1998). Finally, Dunn et 
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al in 2000 illustrated that Wnt signalling is necessary for melanocyte growth and 
differentiation.   
These signalling pathways also control several transcription factors and their 
downstream genes during melanocyte development from neural crest cells. The key 
transcription factors involved in this process are FOXD3, SOX9, SOX10, PAX3 and 
MITF. Activation of precise transcription factor decides the fate of the melanoblast 
precursor cells if it will differentiate to melanocytes or glial cells.  
Microphthalmia-associated transcription factor (MITF) is a basic helix-loop-helix 
transcription factor that is considered as the master regulator of melanocyte 
development. It regulates three major genes (TYR, TYRP1 and DCT) which are 
responsible for pigmentation in melanocytes (Levy et al., 2006). Mice with MITF 
mutations cannot form melanocytes and retinal pigment epithelial (RPE) cells 
couldn’t develop properly (Steingrimsson et al., 2004). MITF helps in the survival of 
melanocytes by directly regulating the key antiapoptotic gene BCL2 (McGill et al., 
2002).  However, the expression of MITF is regulated by an array of upstream genes 
and these genes also play a central role in neural crest development and 
differentiation. It is, therefore important to highlight the role of these genes during 
several steps of melanocyte development. The main transcription factors which 
regulate MITF expression in melanocyte development are SOX10 and PAX3. In both 
human and mouse, a mutation in SOX10 or PAX3 gene results in Waardenburg 
syndrome, which is similar to the effect of mutation in MITF (Tachibana et al., 2003). 
Mutation in these genes can lead to the abnormal melanocyte development which 
could alter the melanin production.  In addition to this SOX10 and PAX3 work 
synergistically to activate MITF expression since SOX10 and PAX3 binding sites are 
next to each other on MITF promoter (Potterf et al., 2000). Taken together these 
results suggest that SOX10, PAX3 and MITF are the key genes required for the 
melanocyte differentiation and melanin synthesis. But there are other transcription 
factors which are active in very early stage of embryonic development and define the 
fate of melanocyte development.                      
FOXD3 is an important transcription factor which is expressed in migrating neural 
crest cells that differentiate into glia and neurons but not detected in later migrating 
neural crest cells which give rise to melanocytes. Kos et al in 2001 using avian 
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neural crest cells discovered two important roles of FOXD3 in neural crest 
development. FOXD3 expression was found in pre-migratory neural crest cells but 
was downregulated in pre-migratory melanoblast lineage. This suggests that FOXD3 
assists in the segregation of the neural crest lineage from the neural epithelium. 
Also, knocking down FOXD3 in vivo led to an increase in neural crest cells 
differentiating into melanocyte whereas the overexpression of FOXD3 suppresses 
melanocyte formation suggesting the role of FOXD3 in suppressing melanogenesis. 
FOXD3 represses melanogenesis by inhibiting binding of PAX3 to the MITF 
promoter (Thomas and Erickson, 2009). In another study, it was shown that Snail 
2, SOX9 and FOXD3 are expressed in the dorsal neural tube suppressing 
melanogenesis. In later stages, the expression of these genes is lost and progress 
towards melanocyte differentiation (Nitzan et al., 2013).  
Another decisive gene which is expressed during neural crest development is SOX2. 
Its expression was not found in pre-migratory and migratory neural crest cells and 
misexpression of this gene lead to the inhibition of neural crest formation 
(Wakamatsu et al., 2004). Therefore, the expression of FOXD3 and SOX2 decides 
the fate of neural crest cells if they will differentiate into melanoblast lineage or glial 
cells.  
Several studies have discovered the role of other genes in neural crest development. 
Some of the important genes are MSX, cMYC, Id3, TWIST and endothelins 
(Baynash et al., 1994) (Steventon et al., 2005). 
 
1.2.2 Pathways and genetics of melanoma development 
The mechanism behind the transformation of melanocyte to melanoma is still not 
clearly understood. Even though, a large body of evidence suggest the role of 
mutations acquired by several genes in melanoma progression. Miller and Mihm in 
2006 proposed a model explaining the different events and molecular changes 
during melanoma progression. The model depicted that the mutations are acquired 
as early as in benign nevi. During the course of transformation, more mutation 
burden helps in the metastasis of the melanoma cells (Figure 1). Mutation in these 
genes alters key signalling pathway which leads to melanoma progression and 
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metastasis. Recently melanoma has been majorly grouped into four categories 
based on their mutational status- BRAF mutant, NRAS mutant, NF-1 mutant and 
Triple wild type (Akbani et al., 2015). 
 
 
 
 
 
 
 
 
Figure 1: Melanocyte to melanoma development. BRAF is an early event during 
melanoma development which is followed by other mutations like loss of tumour 
suppressor genes like CDKN2A, PTEN and NF1. Increased in Id protein expression 
is also found as early as during nevi formation. 
1.2.2.1 MAPK pathway 
Mitogen-activated protein kinases (MAPK) pathway is an intracellular signal 
transduction pathway which regulates cell survival, differentiation, migration and 
proliferation (Torii et al., 2006) (Dhillon et al., 2007). This signalling pathway can be 
activated via various extracellular stimuli like receptor tyrosine kinase (RTK), G-
protein coupled receptors (GPCRs), mitogens and integrins (Zhang and Liu, 2002). 
Upon activation, the downstream protein i.e. RAS, RAF, MEK1/2 and ERK1/2 are 
activated and regulates the above described cellular processes (Kim and Choi, 
2010). Mutation in any of these genes could activate the MAPK pathway and lead to 
uncontrolled cell growth and proliferation.  
BRAF is one of the most mutated genes in this pathway. Several studies have found 
that approximately 40-60% of melanoma patients carry a mutation in BRAF (Davies 
et al., 2002) (Akbani et al., 2015). It is well documented that 90% of BRAF mutation 
Melanocytes Melanocytic Nevus Melanoma 
BRAF mutation 
NRAS mutation 
CDKN2A & PTEN loss 
Loss of NF1 
Increased Id protein 
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have V600E mutation where Valine (V) is substituted by Glutamate (E) at codon 600 
(Tan et al., 2008). Since the mutation occurs in the kinase domain of the BRAF it 
constitutively activates BRAF which further lads to the activation MEK/ERK pathway. 
Interestingly it has been reported that BRAF mutation is more common in 
melanomas arising on the skin which is intermittently exposed to the sun compared 
to sun damaged skin (Maldonado et al., 2003). Conversely, data suggests that 
BRAF mutation is an early event and has been found to be mutated in melanocytic 
nevi (82%) as well (Pollock et al., 2003). Principally BRAF activates downstream 
MEK-ERK pathway which further leads to unchecked proliferation and growth. 
Through MEK-dependent activation of HIF-1α and VEGF, it also promotes 
metastasis and angiogenesis (Maurer et al., 2011). It is also important to note that 
BRAF mutation alone is not able to transform the melanocyte to melanoma. For 
example, BRAF mutation alone in Zebra fish gave rise to nevi but not melanoma. 
More interestingly, Zebra fish with BRAF and additional mutation for P53 generated 
nevi and later formed invasive melanoma (Patton et al., 2005). 
Another key gene which is found to be mutated in melanoma patients is NRAS. In 
1984 RAS activation was first identified in human melanoma cell lines as well in a 
short-term cell culture from a melanoma patient (Padua et al., 1984) (Albino et al., 
1984). Approximately 20% of melanoma patients carry a mutation in NRAS gene 
(Jakob et al., 2012). The most frequent mutations found in this gene are Q61R and 
Q61K. Moreover, it has been found that patient with NRAS mutations are older and 
have chronic sun damaged skin. The tumour thickness in NRAS mutated melanoma 
patients has a greater Breslow index (Devitt et al., 2011). The report also suggests 
that BRAF and NRAS mutations are mutually exclusive and less than 1% of patients 
carry a mutation in both genes at the same time (Goel et al., 2006). 
Neurofibromin 1(NF1) is a tumour suppressor gene which is significantly mutated in 
the MAPK pathway. Approximately 15% of melanoma patients have inactivation or 
loss of NF1 gene. NF1 negatively regulates RAS signalling by hydrolysing RAS-GTP 
(active form) to RAS- GDP (inactive form) (Rajkumar and Watson., 2016). Loss or 
inactivation of NF1 results in unchecked RAS activation which further activates 
MAPK pathway. Similar to NRAS mutated melanoma patients, NF1 mutations have 
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been reported in older patients with chronic sun damaged skin (Krauthammer et al., 
2012) (Mar et al., 2013). 
1.2.2.2 p53 Pathway   
p53 is another tumour suppressor gene which has been reported to be mutated in 
several cancer types including melanoma (approximately19%) (Hodis et al., 2012). 
In melanoma, mutations in several genes have been implicated to circumvent P53 
mediated tumour suppression. CDKN2A is a well-known tumour suppressor gene 
which is frequently mutated in high-risk melanoma family (Aitken et al., 1999). Loss 
of CDKN2A is significant for melanoma progression because it encodes two tumour 
suppressor proteins through alternative splicing i.e. p16INK4a and p14ARF. 
p16INK4a is a cyclin-dependent kinase inhibitor which activates retinoblastoma (RB) 
by blocking the CDK4.  On the other hand, p14ARF regulates the level of p53 protein 
via mouse double minute 2 (MDM2). MDM2 is responsible for the degradation of p53 
through ubiquitination but it is negatively regulated by p14ARF. Subsequently, it 
allows p53 to arrest the cell cycle in G2-M phase to either repair the damaged DNA 
or initiation of apoptosis (Harris and Levine, 2005). It was also shown in vivo that 
loss of p16INK4a and p14ARF reduces the time to develop melanoma on exposure 
to UV light (Recio et al., 2002). These data also clarifies that the low rate of p53 
mutations in melanoma is because of loss of p14ARF. 
1.2.2.3 PI3K/AKT pathway  
The PI3K/AKT signalling pathway is another significant pathway for cellular 
proliferation, survival and migration. This pathway is more often activated by various 
cancer types including melanoma (Cantley, 2002) (Davies, 2012). More often 
activation of PI3K/AKT pathway in melanoma is either due to mutation in PI3K and 
AKT or deletion of PTEN locus on chromosome 10 (Davies, 2012). It is important to 
note that PI3K can also be activated by activated RAS proteins (Mendoza et al., 
2011). PTEN is a potent tumour suppressor which keeps in check the PI3K/AKT 
pathway by keeping the phosphatidylinositol phosphate (PIP3) level low. In 
melanoma, loss of PTEN (20-30%) allows the accumulation of PIP3 which further 
activates AKT. Phosphorylated AKT results in inactivation of Bcl-2-antagonist-of-cell-
death as a result tumour cell escapes apoptosis. Two another crucial protein in this 
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pathway is mTOR and GSK3b which is found to be activated in metastatic 
melanoma and results in tumour growth (Karbowniczek et al., 2008) (McCubrey et 
al., 2014) Several in vivo and in vitro studies have shown that loss of PTEN and 
activation of AKT promotes growth and survival of melanoma cells (Wu et al., 2003) 
(Cantley and Neel, 1999) 
1.2.2.4 Wnt signalling pathway 
The Wnt signalling pathway is crucial during embryonic development and in 30% of 
melanoma constitutive activation of Wnt signalling has been found. However, its role 
in melanoma is still not clearly understood. β-catenin is the key member of Wnt 
signalling canonical pathway and regulates cell-cell adhesion. Interestingly 23% of 
human melanoma cell lines show a mutation in β-catenin. In a study researcher used 
a mouse model carrying PTEN loss and BRAF-V600E mutation, which can develop 
the tumour in 100% of the mouse within 1 month, showed that loss of β-catenin can 
lead to inhibition of melanoma formation (Damsky et al., 2011). Recently in another 
study, it was found that β-catenin activation promotes lung metastasis in NRAS-
mouse (Gallagher et al., 2013). On the contrary, expression analysis of β-catenin 
using immunostaining showed that only 38% of metastatic melanoma were positive 
compared to melanocytic nevi (95%), radial (94%) and Vertical (65%) growth phase 
primary melanoma (Kageshita et al., 2001). These data indicates that β-catenin 
could be more involved during the early phase of melanoma progression. 
Similarly, in other study using mouse melanoma cell line, it was shown that Wnt3a 
expression is responsible for differentiation in melanoma cells and it displays slow 
proliferation and reduced migration. However, expression of Wnt5a in the same cell 
line antagonises the gene expression activated by Wnt/β-catenin signalling (Chien et 
al., 2009). Wnt5a inhibits the canonical pathway by binding to the Fzd receptor. 
Wnt5a binds to Frizzled2 (Fzd2) and prevents the phosphorylation of lipoprotein 
receptor-related protein 6 (LRP6) by Wnt3a, therefore reducing the accumulation of 
β-catenin (Sato et al., 2010). Additionally, inhibition of β-catenin by Wnt5a results in 
suppression of LEF1 and upregulation of TCF4 which generates more invasive 
phenotype (Eichhoff et al., 2011). These data suggests the effect of Wnt signalling 
pathway is more dependent on cellular context and more investigation is needed in 
this area. 
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1.2.2.5 Tgf-β pathway 
Transforming growth factor-beta (Tgf-β) pathway is activated during various cellular 
processes like proliferation, differentiation, cell survival, extracellular 
microenvironment modification, migration. It has been well established that Tgf-β 
initially works as a tumour suppressor and later helps in tumour progression. In 
normal melanocytes only Tgf-β1 is expressed whereas in melanoma cells all 3 
isoforms of Tgf-β (Tgf-β1, Tgf-β2 and Tgf-β3) are secreted (Javelaud et al., 2008). 
As a tumour suppressor, Tgf-β checks proliferation in cells by activating cyclin-
dependent inhibitor (CDKI) (p21, p15, p27Kip1 and p57Kip2), c-MYC and inhibitor of 
differentiation (Id). Experimental data shows that Tgf-β reduces melanocyte 
proliferation by arresting the cell cycle in G1 phase and stops differentiation by 
downregulating PAX3 which along with SOX10 controls melanocyte differentiation 
(Yang et al., 2008). However, during the later stage of tumour progression, Tgf-β 
promotes metastasis by inducing epithelial to mesenchymal transition (EMT) and 
also helps tumour cell escaping immune surveillance (Perrot et al., 2013). A recent 
finding from our laboratory shows that Tgf-β1 induces SOX2 expression to promote 
melanoma invasion in vitro (Weina et al., 2016).  
1.2.2.6 TERT promoter mutation 
Two independent studies in 2013 discovered that telomerase reverse transcriptase 
(TERT) is mutated in familial and sporadic melanoma patients. Whole genome 
sequencing data found two mutations in the promoter region of the TERT gene. This 
mutation in the promoter sequence lead to the creation of new binding motifs for the 
Ets- transcription factor family and increases its transcriptional activity by 2-4 folds. 
In human metastatic melanoma cell lines, 125 out of 168 (74%) were found with 
somatic mutation in TERT promoter (Horn et al., 2013) (Huang et al., 2013). Horn 
et al did not report any TERT promoter mutation but  a recent report shows low 
frequency mutation in benign nevi (Horn et al., 2013) (Shain et al., 2015). More 
studies with larger data set are required to investigate the role of TERT mutation in 
melanoma progression. 
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1.3 Melanoma Treatment 
Due to the heterogeneity of melanoma tumour, treatment of melanoma patient 
depends on several factors like stage and mutations. If detected in primary stage 
excision is still the first line of treatment for melanoma. Depending upon the tumour 
thickness and lymph node biopsy the further direction of treatment is decided. Before 
the arrival of 2nd generation drugs for melanoma treatment, the most commonly used 
cytotoxic chemotherapy was dacarbazine and immunotherapies like interleukin-2 (IL-
2). These treatments can be used either as monotherapy or in combination (Bhatia 
et al., 2009). Currently, for the treatment of metastatic melanoma, several lines of 
therapy can be followed and this can be grouped into chemotherapy, immunotherapy 
and targeted therapy. 
1.3.1 Targeted therapy 
A number of melanoma patients have deregulated MAPK pathway which is due to 
mutations in either BRAF or NRAS gene. In 2011 the first BRAF inhibitor, 
Vemurafenib (PLX4032), was approved by FDA for the treatment of late-stage 
melanoma with BRAF (V600E) mutations (Bollag et al., 2012). The clinical trial data 
showed improved rates of overall and progression-free survival in patients treated 
with vemurafenib compared to patients treated with dacarbazine. Also, it was 
observed that patient-group treated with vemurafenib compared to dacarbazine 
displayed a relative reduction of 63% in the risk of death and of 74% in the risk of 
either death or melanoma progression (Chapman et al., 2011).  In 2012, another 
BRAF inhibitor, dabrafenib (GSK2118436), was reported to show significantly better 
progression-free survival compared to dacarbazine in melanoma patients with BRAF 
(V600E) mutations (Hauschild et al., 2012). Later, in the year 2013 FDA approved 
the use of dabrafenib for the treatment of melanoma carrying BRAF (V600E) 
mutation. Additionally, dabrafenib displayed similar treatment benefits on melanoma 
patients with the mutation on BRAF (V600K/D/R) (Gentilcore et al., 2013) (Ascierto 
et al., 2013). However, after 6-7 months most of the patients receiving vemurafenib 
or dabrafenib show relapse of the tumour and develop resistance to the treatment. In 
another strategy to stop the activation of MAPK pathway in melanoma patients, new 
small inhibitors were examined to block MEK1/2 proteins. MEK inhibitors were 
supposed to block the MAPK pathway in melanoma carrying either NRAS or BRAF 
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mutation. Trametinib (GSK1120212) and Cobimetinib (GDC-0973, XL-518) are the 
MEK-inhibitors approved by FDA in 2013 and 2014 respectively for the treatment of 
melanoma patient with BRAF mutation. Trametinib functions by binding to MEK1 and 
MEK2 whereas cobimetinib blocks MEK1 resulting in inhibition of tumour cell growth. 
Later on, combination therapy of trametinib and dabrafenib was approved by FDA for 
the treatment of the patient with BRAF V600E/K mutation. Whereas, cobimetinib was 
approved to be used in combination with vemurafenib. Even though the effect of the 
targeted therapy was evident but adaptive resistance to these therapies limits the 
efficacy of the treatment.  
In some cases like patients carrying a C-KIT mutation in melanoma (acral 
melanoma, mucosal or in chronic sunburn areas), imatinib and nilotinib can be used 
for the treatment (Murer C et al., 2017). 
1.3.2 Immunotherapy 
Melanoma is one of the most immunogenic tumours and therefore immunotherapy 
can be used to boost the immune system of melanoma patients to attack the tumour 
cells. Interferon alpha (IFN-α) and IL-2 were the first immunotherapy approved for 
the treatment of patients with metastatic melanoma (Bhatia et al., 2009). Clinical 
trial study with 270 metastatic melanoma patients showed that high dose of bolus IL-
2 (HD IL-2) results in 16% overall objective response rate (6% complete response 
and 10% partial response) (Atkins et al., 1999). IFN-α showed an overall response 
rate of 22% in phase II trial with metastatic melanoma patients (Creagan et al., 
1986). However, the major drawback of this approach was the heavy side effects 
and many patients were not able to take the high dose.   
In last decade, a better understanding of tumour immunology led to the discovery of 
new insights for targeting the tumour cell using the immune system. An example of 
two such approaches is targeting cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4) and programmed cell death protein 1 (PD-1). CTLA-4 is a protein receptor 
expressed by T-regulatory cells on their surface that inhibits T-cells and immune 
response. Dendritic cells present antigen produced by cancer cells to cytotoxic T- 
lymphocytes (CTLs) and then CTLs attack the cancer cells.  
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Ipilimumab is the human monoclonal antibody which binds to CTLA-4 and blocks its 
inhibitory action. In a randomised, double-blind, phase III trial, 676 stage III-IV 
melanoma patients were registered based on HLA-A*0201 positive status. These 
patients were assigned into 3 groups and treated with ipilimumab plus glycoprotein 
100 (gp100), ipilimumab only and gp100 only. In this study, it was found that patient 
treated with or without gp100 showed improved overall survival compared to the 
patient treated with only gp100 (Hodi et al., 2010). In another phase III trial with 502 
patients, similar results were obtained. Patients were equally divided into two groups 
and either treated with ipilimumab plus dacarbazine or dacarbazine plus placebo.  It 
was shown that the overall survival after one year in the patient group treated with 
ipilimumab plus dacarbazine were significantly higher (11.2 months) compared to 
(9.2 months) in the dacarbazine plus placebo. This study brought ipilimumab as the 
first line of treatment for metastatic melanoma (Robert et al., 2011) 
PD-1 is another receptor which is expressed in activated T cells and when its ligand 
PDL-1 and PDL-2 binds to this receptor it promotes self-tolerance by reducing auto-
immunity. In 2014 FDA approved two drugs, Nivolumab and Pembrolizumab, for 
metastatic melanoma that targets PD-1 receptor and augments the immune system 
to kill tumour cells. In a study involving 296 patients with advanced melanoma (104), 
non-small-cell lung carcinoma (122), castration-resistant prostate cancer (17), or 
renal-cell (34) or colorectal cancer (19) were given nivolumab (BMS-936558). In a 
cohort of melanoma patients, 26 objective responses were detected at doses 
ranging from 0.1 to 10.0 mg per kilogram, with response rates stretching from 19% to 
41% per dose level (Topalian et al., 2012). In another phase III clinical trial with 834 
patients with metastatic melanoma, it was observed that patients treated with 
pembrolizumab showed higher progression-free survival and overall survival 
compared to ipilimumab. High-grade toxicity in pembrolizumab treated patient was 
not as much of ipilimumab treated patients (Robert et al., 2015). 
 
1.4 Drug resistance in melanoma 
In recent years due to the approval of new generation drugs against metastatic 
melanoma, the overall survival has improved but resistance against these drugs limit 
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the therapeutic advantage. Data from several studies have revealed that majority of 
the resistance cases are associated with targeted therapy especially BRAF inhibitors 
but recent data also highlights resistance to the current immunotherapies. 
Furthermore, it was found that this resistance can be either intrinsic or adaptive. 
Patients with intrinsic resistance do not show any response to the therapy whereas 
adaptive resistant patients show early response to the treatment but later they show 
no effect of the therapy.  This was elucidated by whole genome sequencing of BRAF 
positive melanoma patients before treatment and after developing resistant. 
Interestingly, it was found that one-fifth of melanoma patients with BRAF mutation 
does not respond to the therapy. Varied resistance mechanisms cultivate during 
target therapy but mostly involve the reactivation of MAPK pathway (Van Allen et 
al., 2014). Earlier it was shown that the resistance to BRAF inhibitor (SB590885) 
was gained through overexpression of cyclin D1 and enhanced by high levels of 
CDK4 expression (Smalley et al., 2008). In addition, loss of NF1 and increased 
expression of protein kinase D3 (PRKD3) has been connected to the regulation of 
MAPK pathway and melanoma resistance (Whittaker et al., 2013) (Chen et al., 
2011).  
A large number of melanoma patients display significant response to the BRAF or 
MEK inhibitor initially but develops resistance later; this mechanism is described as 
adaptive resistance. Recent investigations suggest that the reactivation of ERK 
signalling is one of the main reasons behind the resistance in these melanoma 
patients. It is interesting to note that there was no secondary gatekeeper mutation 
found in BRAF inhibitor resistant patients but additional mutation on NRAS was 
identified (Nazarian et al., 2010) (Tap et al., 2010). However, several studies have 
reported the amplification of mutant BRAF as one of the mechanisms for BRAF and 
MEK inhibitor resistance (Corcoran et al., 2010) (Villanueva et al., 2013). Besides, 
it was found by random mutagenesis and biochemical studies that mutation in CRAF 
activates MAPK pathway which further leads to resistance (Antony et al., 2013). In 
another study, COT kinase was identified activating ERK through MAPK and linked 
to resistance in BRAF and MEK inhibitor resistance (Johannessen et al., 2010). 
COT kinase is encoded by MAP3K8 and it is overexpressed after treatment with 
BRAF or MEK inhibitor thus conferring resistance. 
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Numerous studies have indicated that additional pathways other than ERK1/2 
pathway are activated in BRAF inhibitor resistant melanoma cell lines. In BRAF 
resistant patients platelet-derived growth factor receptor β (PDGFRβ) receptor 
tyrosine kinase is upregulated. Additionally, the BRAF inhibitor resistant cell lines 
showed inactive ERK pathway but they were dependent on PDGFRβ for growth and 
survival (Nazarian et al., 2010). Recently another group showed the role of PDGFRβ 
and EGFR in adaptive resistance to BRAF inhibitor. EGFR expression was 
upregulated in 6 out of 16 melanoma tumours after the development of resistance to 
BRAF or MEK inhibitor. Also, they found that upon silencing SOX10 expression 
leads to activation of Tgf-β signalling which further leads to increased expression of 
EGFR and PDGFRβ (Sun et al., 2014). One study gives experimental evidence that 
AXL receptor tyrosine kinase is also expressed in resistant melanoma tumours 
besides EGFR and PDGFRβ. The ratio between MITF and AXL (MITFlow/AXLhigh) 
expression is crucial in certain BRAF and NRAS mutated melanoma which drives the 
resistance mechanisms (Müller et al., 2014). Another RTK, for example, insulin-like 
growth factor receptor-1 (IGF-1R), was identified which is constitutively active in 
BRAF resistant cells. Elevated IGF-1R expression in BRAF resistant melanoma cells 
was correlated with PI3K/AKT pathway (Villanueva et al., 2010). While 
immunotherapy like anti-PD-1 exhibited remarkable success in terms of overall 
survival and efficacy, it has been also indicated that approximately 60% patients 
show primary resistance whereas about 25% patients tend to develop resistance 
subsequently (Topalian et al., 2012) (Zaretsky et al., 2016). Lately, it has been 
found that clonal selection of tumours for JAK1 and JAK2 mutations and loss of IFN-
γ signalling pathways or loss of B2M gene (decreased antigen presentation) is a 
possible mechanism for the development of resistance in patients with anti-PD-1 
therapy (Zaretsky et al., 2016). In order to circumvent these resistances in 
melanoma patients, several combinational therapies have been tested and approved 
recently.  
 
1.4.1 Melanoma dedifferentiation  
Melanoma is the malignant transformation of melanocytes and melanocytes are 
differentiated from nReural crest cells. The neural crest cells are transient 
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multipotent migratory cells. Based on several studies, it is evident that melanoma is 
comprised of a highly heterogeneous population of cells. Within this heterogeneous 
population of cells, there is a sub-population which dedifferentiates and recapitulates 
some of the neural crest cells phenotype. Those cells demonstrate phenotype like 
self-renewal, low proliferation rate, and highly resistance to therapies (Boiko et al., 
2010) (Larribere and Utikal, 2014). The dedifferentiation theory was also supported 
by Landsberg et al in 2012, where they have demonstrated that the pro-
inflammatory cytokine, TNF-α, can lead to dedifferentiation in mouse and human 
melanoma cells. Here they also showed that after adoptive cell transfer therapy 
(ACT) the relapse of tumour in metastatic melanoma patients after significant 
regression was due to the gain of gene expression related to neural crest cells like 
P75 (also known as CD271 or NGFR) (Landsberg et al., 2012). A large body of 
work has deciphered the expression and role of numerous other genes associated 
with dedifferentiation during melanoma progression.  
 
1.4.1.1 CD271 (P75/NGFR) 
CD271 is a low-affinity transmembrane protein and a member of Tumor Necrosis 
Factor Receptor (TNFR) superfamily (Rogers et al., 2008). During development, 
CD271 is expressed in neural crest stem cells also expressed in various adult 
tissues and tumours originating from neural crest or ectoderm. As reported in a study 
where they used CD271 as melanoma stem cell marker for identification and 
isolation. CD271+ and CD271− cells when injected in mouse, only CD271+ cells 
metastasized to liver and lung. Furthermore, the experimental data indicated that 
CD271+ cells either completely or partially lacked melanocytic marker like Tyr, 
MART-1 and MAGE (Boiko et al., 2010). In accordance with previous data, Civenni 
et al in 2011 confirmed that CD271+ cells are more tumorigenic compared to 
CD271− as well they show tumour heterogeneity similar to the parental tumour.  
Together, in vitro and in vivo results suggested that CD271+ cells have higher self-
renewal capacity with longer propagation compared to CD271− cells. Additionally, 
CD271+ melanoma cell population expresses low MITF and migrate faster than 
CD271− cells (Cheli et al., 2014). Recently it has been shown that the expression of 
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CD271 in melanoma cells promotes metastasis and drug resistance in a p53-
dependent manner especially in BRAF wild-type cell lines (Redmer et al., 2017).   
 
1.4.1.2 ABCB5 (ATP-binding cassette subfamily B member 5) 
ABCB5 is a member of ATP-binding cassette (ABC) transporter superfamily and 
involved in the transportation of a variety of compounds like sugar, peptides and 
small ions in the cell (Chen et al., 2005). ABCB5 was shown to be expressed in a 
subset of melanoma cells which were chemoresistant and demonstrated stem cell 
like phenotype (Frank et al., 2005). Through immunostaining, it was determined that 
the expression of ABCB5 was significantly higher in primary and metastatic 
melanoma compared to the nevus. Furthermore, ABCB5+ population showed 
sustained tumour growth than ABCB5− cell population and also reinstate the tumour 
heterogeneity. In the same study, in vivo genetic lineage tracking confirmed the role 
of ABCB5 in self-renewal and differentiation. (Schatton et al 2008). Interestingly, the 
circulating tumour cells (CTC) exhibited a significantly higher frequency of ABCB5+ 
cells (33.4%) compared to the primary and metastatic tumours. Similar to previous 
findings, ABCB5+ CTC were more tumorigenic and promote metastasis (Ma et al., 
2010). Recently, the same group has reported the role of ABCB5 in melanoma 
growth and multi-drug resistance. In addition, ABCB5 promotes tumour growth by 
induction of IL8 through Wnt signalling pathway and also represses tumour 
suppressor WFDC1. At last ABCB5 was implicated in tumour growth, resistance, 
quiescence and melanoma-initiating cells renewal (Wilson et al., 2014). 
 
1.4.1.3 SOX2 
SOX2 (sex-determining region Y (SRY) Box2) is a transcription factor which is 
expressed in neural crest stem cells. Several studies have established the role of 
SOX2 in melanoma progression. The SOX2 expression has been correlated with 
tumour thickness and bad prognosis (Laga et al., 2010). In vitro and in vivo data 
suggests the role of SOX2 in cell proliferation and apoptosis. Knocking down SOX2 
using shRNA resulted in smaller melanoma initiating cell spheres, whereas the 
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SOX2 overexpression leads to higher and bigger melanoma- initiating cells spheres 
(Santini et al., 2014). Next, they showed that HH-GLI (HEDGEHOG-GLI) signalling 
pathway directly regulates SOX2 expression by binding of GLI1 and GLI2 on SOX2 
promoter and induces stemness in melanoma cells. Moreover, the SOX2 expression 
has also been correlated with drug resistance in several cancer types (Weina and 
Utikal, 2014) (Weina et al., 2016). 
 
1.4.1.4 CD133 
CD133 is found to be expressed in neural stem cells, cancer stem cells in brain 
tumour and hematopoietic stem cells (Sanai et al., 2005) (Singh et al., 2004) (Horn 
et al., 1999). Immunostaining has revealed that CD133 expression is significantly 
higher in primary (39.4%) and metastatic melanoma (46.4%) compared to nevi 
(16.9%) (Klein et al., 2007). Another group reported that less than 1% of melanoma 
specimens comprise CD133+ cells. More importantly, only CD133+ cells form visible 
tumour compared to CD133− when injected into an NOD-SCID mouse. WM115 is 
highly tumorigenic human melanoma cell line and almost 95% of WM115 cells 
express CD133 along with ABCG2. Although the expression level of these markers 
reduces in xenograft tumours which again increases when cultured in vitro. But 
interestingly WM115 cell line expresses lymphoangiogenic and angiogenic factors 
like VEGFR-3, LYVE-1, prox1 and podoplanin which promotes metastasis (Monzani 
et al., 2007). Altogether these findings recommend that CD133 is essential for the 
maintenance and promotion of melanoma-initiating cells. 
 
1.5 Id protein 
Inhibitor of differentiation (Id) protein belongs to the helix-loop-helix (HLH) 
superfamily. It was first discovered in 1990 by Benezra and his colleague (Benezra 
et al., 1990). In vertebrates four members of this family i.e. Id1, Id2, Id3 and Id4 have 
been identified. The members of Id family are found on different chromosomes- Id1-
20q11, Id2-2p25, Id3-1p36.1 and Id4-6p21-p22; therefore, they are not isoforms 
rather different proteins (Benezra et al., 1990) (Roschger and Cabrele, 2017). All 
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four members are well conserved and found in organisms ranging from drosophila to 
human. Although, Id protein shares the HLH domain but outside this domain, they 
display broad differences in their sequences (Langlands et al., 1997). More 
importantly, Id protein cannot bind to the DNA due to lack of basic domain but they 
can form heterodimers with other bHLH (basic helix-loop-helix) proteins. The binding 
of Id protein to bHLH transcription factor leads to inhibition of its binding to the DNA. 
For example, E protein family (E12, E47) are the class I bHLH transcription factor 
which when sequesters with Id proteins cannot bind to the DNA and negatively 
regulates the gene expression. Therefore, the crucial biological significance, 
common to all four Id proteins is blocking the activity of bHLH in a tissue-specific 
manner (Deed et al., 1996) (Massari and Murre, 2000).  
1.5.1 Id protein structure and localisation  
As mentioned earlier and showed in the Figure 2 , the HLH domain is highly 
conserved in all Id protein but the N-terminal and C-terminal of Id protein vary from 
each other and also comprises of crucial regulatory signals like ubiquitination, 
phosphorylation site etc. In a study, it was well demonstrated through mutagenesis 
that protein kinase A (PKA) phosphorylates Id1 at ser-5 and also stops its nuclear 
export (Nishiyama K et al., 2007). Whereas in another study it has been shown that 
Cdk2 phosphorylates Id2 and Id3 at ser-5 (Deed et al., 1997) (Hara et al., 1997).  
Bounpheng et al in 1999 showed that Id proteins have short half-life nearly 20 min. 
By inhibiting the 26S proteasome it was found that Id1, Id2 and Id3 proteins are 
degraded via the ubiquitin-proteasome pathway. In addition, it was reported that the 
co-expression of E47 and Id3 protects Id3 from degradation and increases its half-
life (Deed et al., 1996). It was observed that Id4 degradation was not established via 
26S proteasome but through E1 enzyme. (Bounpheng et al., 1999). Interestingly, 
the Id1, Id2 and Id3 are protected from degradation by the deubiquitinase USP1 to 
preserve their stemness in mesenchymal stem cells USP1 (Williams et al., 2011).  
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Figure 2: Human Id proteins structure and their mode of action. A, B. N-terminal 
and C-terminal amino acid sequence alignment of the Id proteins. Id1’ and Id3L are 
the C terminus of human Id1 and Id3 spliced form. C. Alignment of amino acid 
sequence of the HLH domain of four Id proteins as well (D) the structural difference 
of Id proteins (HLH) with bHLH proteins. E. Schematic representation of Id protein 
forming a heterodimer with E-protein in state1(left panel) and inhibiting its binding to 
the E-box of the promoter. State 2 (Right panel) shows the activation of transcription 
when two bHLH forms homo or heterodimer. This figure was modified from Roschger 
C and Cabrele C, 2017 and Perk J et al., 2005. 
N-terminal 
C-terminal 
(E47) 
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Id proteins are small proteins which may be found in the cytoplasm and nucleus. 
Although Id proteins do not have the canonical nuclear localisation signal (NLS) 
motif, Id1 and Id2 have nuclear export signal (NES) motif in the HLH domain and in 
the C-terminus respectively (Makita et al., 2006) (Kurooka et al., 2005). However, 
Id3 proteins have no such nuclear localisation signals like Id1 and Id2 but HLH 
domain is enough for its nuclear localisation. It was found that Id3 is localised more 
in the nucleus in the presence of E47 while found more in the cytoplasm or 
perinuclear region in the absence of E47 (Deed et al., 1997). This finding suggests 
that that the NLS motif of bHLH could act as a transporter of Id protein in the 
nucleus. 
1.5.2 Id protein regulation 
As discussed earlier, Id proteins negatively regulates bHLH transcription factor 
functions and stops the cell from differentiation. There is overwhelming evidence 
which shows that the expression of Id protein is higher in undifferentiated, very 
proliferative and embryonic cells (Ruzinova et al., 2003) (Engel and Murre, 2001) 
(Lasorella et al., 2001) (Ling et al., 2014) (Tzeng and De Vellis, 1998). Several 
studies have shown the activation of Id gene in stem cells and progenitor cells to 
enhance the proliferation and suppress the differentiation, but the gene expression is 
deactivated during lineage specification and differentiation (Norton, 2000). In vitro 
and in vivo data suggests that BMP2/4 is instrumental in the induction of Id1, Id2 and 
Id3 expression in a variety of cells including embryonic stem cells (Hollnagel et al., 
1999). It was very recently shown using the human embryonic carcinoma cell line 
NTera2 that the nuclear factor Y (NFY) transcription factor directly regulates the Id1, 
Id2 and Id3 gene expression. The loss of NFYc was observed on differentiation 
which also resulted in the reduction of Id1-3 gene expression (Moeinvaziri and 
Shahhoseini, 2015). Id1 gene has enhancer element at the 3’-end which can be 
activated by transcription factors C/EBPβ and STAT5. Therefore, Id1 is highly 
expressed in myeloid cells due to the critical role of C/EBP family in these cells. IL-3 
and GM-CSF can activate STAT5 which could further result in the induction of 
Id1gene expression (Saisanit and Sun XH 1997) (Xu M et al., 2003) (Cochrane, 
2009). Another report confirmed the presence of C/EBPβ binding sites in the 
promoter region of Id2 and showed that it is directly regulated by C/ EBPβ (Karaya 
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et al., 2005). However, it was illustrated that in immature thymocytes, Id3 
transcription was activated by Egr1 via Ras-MAPK pathway. This is a critical 
phenomenon for the T cell development (Bain et al., 2001). In contrast, it was found 
that in breast cancer E2F1 recruits mutant p53 and directly binds to the Id4 promoter 
and activates it (Fontemaggi et al., 2009).  
1.5.3 Id protein and cell cycle regulation 
A large body of evidence implicates the role of Id proteins in cell cycle regulation. 
Predominantly, Id proteins antagonise the E-proteins by sequestering them and 
several reports suggest the negative regulation of E2A (E12/47) on cell growth. 
Mainly the Id proteins inhibit the activation of genes associated with differentiation for 
example CDK inhibitors (p15, p16 and p21) (Peverali et al., 1994) (Pagliuca et al., 
2000). Id proteins are associated with the regulation of G1-S cell cycle phase. During 
the late G1 phase, Id2 and Id3 are phosphorylated by CDK2 restricting the 
dimerization of bHLH in vitro (Deed et al., 1997) (Hara et al., 1997). In addition to 
CDK inhibitors, other cell cycle regulators like pRB (retinoblastoma) and p53 are also 
affected by Id protein. Only Id2 interacts with pRB directly. By crossing Id2 and Rb 
mutant mouse it was demonstrated that Id2 can rescue the embryonic lethality of Rb
-
/-
 mutant embryos (Lasorella et al., 2000). Additionally, it has been shown both in 
vitro and in vivo that Id2 also interacts with p107 and p130 (Lasorella et al., 1996). 
Although, Id1 and Id3 indirectly regulate the activity of pRb by binding to Ets domain 
proteins or bHLH transcription factors. It leads to the downregulation of p16 or p21 
expression which results in the cyclin/CDK complex formation and finally 
hyperphosphorylation of pRb (Ohtani et al., 2001) (Alani et al., 2001) (Ouyang et 
al., 2002). All these data highlights the importance of Id protein in cell cycle 
regulation. 
1.5.4 Id protein and stem cell maintenance 
The fact that Id protein inhibits differentiation and promotes proliferation supports 
their role in the maintenance of stem cell and progenitor cells. Several research 
groups have proven the expression of Id proteins in embryonic and somatic stem 
cells. For example, in mouse embryonic stem (ES) cells, it was shown that Id 
proteins are the target of BMP/Smad signalling which keeps the ES cells 
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undifferentiated and supports self-renewal (Ying et al., 2003). Earlier also with in 
vivo data, it was shown that Id protein overexpression is correlated with inhibition of 
differentiation in C2C12 muscle cell line (Jen et al., 1992). In hematopoietic stem 
cells (HSCs), Id protein roles have been similarly identified in self-renewal and 
stemness. The comparison between wild-type and Id1−/− marrow revealed the 
decrease in the number of long-term (LT) HSCs (Perry et al., 2007) (Jankovic et 
al., 2007). In the same way, expression of Id1 and Id3 was found in undifferentiated 
human embryonic stem cells (hESCs) and human induced pluripotent stem cell 
(hiPSCs). Double knockdown of Id1 and Id3 in hemogenic precursors enhances 
differentiation into hematopoietic progenitors (Hong et al., 2011). More recently, 
when Id3 was stably overexpressed in endothelial cells (ECs), gave rise to molecular 
stemness signatures like CD133+, VEGFR3+, and CD34+. Also, the Id3 
overexpression significantly increased the G0-G1 phase cells compared to the wild-
type cells and had phenotypes similar to glomeruloid microvascular lesions (Das et 
al., 2015).  
Furthermore, it was shown in GFAP+ astrocytes with stem cell characteristics, a high 
expression of Id1 which could divide asymmetrically into Id1-high stem cell and Id-
low differentiated cells. The neurosphere-formation experiment substantiated that 
high Id1 and Id3 expression are critical for this process and double knockdown of Id1 
and Id3 could reduce the secondary neurosphere formation by 50% (Nam and 
Benezra, 2009). Consequently, it appears that higher Id expression is required to 
preserve the self-renewal ability and preserve the neural stem cells. 
1.5.5 Id protein and development 
Id proteins are expressed at several stages during the development of an organism. 
Over a period of time, a number of animal models with Id gene knockout (KO) have 
been generated to study their role in development. For example, it was observed that 
no embryo survived with Id1-/- Id3-/- beyond E13.5. The reason behind that was the 
cranial haemorrhage due to an aberration in vasculogenesis in the brain. In addition, 
they observed the small brain size in Id1-Id3 double KO embryos which were due to 
premature neural differentiation (Lyden et al., 1999). It is interesting to note that 
embryos lacking 1-3 Id alleles survived and indistinguishable from the wild types. But 
the Id1+/- Id3-/- didn’t support angiogenesis in tumour xenografts due to lack ok αvβ3-
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integrin or MMP2. (Lyden et al., 1999).  Similarly, single knockout of one of the Id 
gene in mouse presented their role during the development. When Id1 was knocked 
out in mouse embryo fibroblast (MEFs), it was found that TSP-1 is the transcriptional 
repressor target of Id1. Due to loss of Id1, increased activity of TSP-1 was observed 
which was responsible for the poor angiogenesis (Volpert et al., 2002). In chick 
embryo, through in situ hybridization, Id2 expression was shown on the dorsal 
cranial neural fold and neural crest. Overexpressing Id2 in chick embryo resulted in 
the conversion of the ectodermal cell to neural crest fate (Martinsen and Bronner-
Fraser, 1998). Whereas Id2 KO mouse revealed that Tgf-β induces Id2 expression 
and lack of Id2 can lead to a defect in the development of dendritic cells (DCs). More 
interestingly, Id2-/- mice also displayed a lack of lymph nodes and Peyer's patches 
(Hacker et al., 2003). Another report has shown that when Id3 null mice were 
generated they exhibited defects in humoral immunity and B cell proliferation. 
However, ectopic expression of Id1 can substitute the role of Id3 in B cell 
proliferation. This can be explained due to the fact that Id1 and Id3 have about 69% 
homology and a minimal level of Id protein is necessary to stop the bHLH dimer 
formation which is the negative regulator of cell cycle progression (Pan et al., 1999). 
The generation of Id4 KO mouse facilitated to study its role in neural stem cell 
development. The result obtained from this study shows that the Id4-/- mouse had 
smaller brain size compared to the mouse carrying Id4 wild type gene. The 
explanation behind this phenomenon was premature differentiation of neural stem 
cells and prolonged G1 to S transition in the early neural stem cells (Yun et al., 
2004). Additionally, the Id4-/- mouse embryos displayed 20-30% reduction in the 
mitotic neural precursor cells (NPCs) and the tunnel assay further revealed an 
increase of 3.5 times in apoptosis of the ventricular zone (VZ). Also, the in vitro data 
from the neurospheres of Id4-/- NPCs showed reduced proliferation and increased 
differentiation of astrocytes in presence of BMP2 (Bedford et al., 2005). 
In skin, expression of Id1, Id2 and Id3 has been found in proliferating human 
keratinocytes which is further decreased with differentiation (Langlands et al., 
2000). An increasing number of studies have also found that Id proteins regulate the 
osteoblast proliferation and bone matrix formation (Peng et al., 2004) (Lee et al., 
2006) (Oh et al., 2012). Similarly, Id proteins play a crucial role during myogenesis 
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by regulating the differentiation of myoblasts as result of blocking E proteins activity 
(Langlands et al., 1997). 
1.5.6 Id protein and cancer  
A growing body of evidence shows that Id proteins play a major role in several 
cancers progression. Their expression has been found to be deregulated in diverse 
tumour types (Figure 3). It becomes even important to know that Id proteins satisfy 
two essential criteria from the hallmarks of cancer i.e. it promotes cell growth and 
attenuates differentiation of the cell (Lasorella et al., 2014). Even though Id proteins 
are involved in tumorigenesis, it doesn’t fit to be classified as a tumour promoter or 
oncogene as there are not enough evidence which claims that Id genes are mutated 
or altered to transform a normal cell into the cancer cell. When Id1 and Id3 were 
sequenced from malignant melanoma-prone families and ovarian tumour 
respectively, no mutation was detected (Casula et al., 2003) (Arnold et al., 2001). 
However a recent report put forward Id4 as an oncogene which is amplified in 32% 
of high-grade ovarian patients (Ren et al., 2012). On contrary, the sequencing data 
of Burkitt’s lymphoma shows that Id3 acts as a tumour suppressor, which is 
inactivated in 68% of the Burkitt’s lymphoma samples (Richter et al., 2012).  But 
what makes Id proteins an important player during tumour development is that Id 
proteins are targets of numerous oncogenes like N-Myc, Ras, Notch and receptor 
tyrosine kinase (Lasorella et al., 2000) (Chadwick et al., 2009) (Reynaud-
Deonauth et al., 2002) (Tam et al., 2008) (Tournay and Benezara 1996) (Bain et 
al., 2001). Along with these oncogenes, there are some growth factors like TGF-β, 
BMP4, VEGF and FGF, which are activated in tumour cells and are positively 
correlated with Id protein expression and regulate cell proliferation, metastasis, 
angiogenesis and invasion (Perk et al., 2005).   
To investigate the role of Id protein in human keratinocytes, Id1 was ectopically 
expressed in these cells. The ectopic expression of Id1 alone resulted in the 
immortalization of human keratinocytes. Remarkably the immortalized cells showed 
reduced differentiated phenotype and furthermore activate the phosphorylation of Rb 
protein. They also demonstrated that ectopic expression of Id1 in human 
keratinocytes results in the impairment of p53 pathway. Additionally, the in vitro data 
showed that Id1, Id2 and Id3 all prolong the lifespan of human keratinocytes by 
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activating the telomerase activity and hTERT expression (Alani et al., 1999). Now it 
is also well-established fact that Id1, which is up-regulated in many tumours 
including melanoma, is a transcriptional repressor of CDKN2A which encodes two 
important tumour suppressor genes- p16INK4a and p14ARF (Ryu et al., 2007). 
Thrombospondin-1 (TSP-1) is another potent tumour suppressor and inhibitor of 
angiogenesis, which is downregulated by Id1 expression in melanoma (Healey et 
al., 2010) (Straume and Akslen, 2005). Metastatic and invasive breast cancer cell 
lines show elevated levels of Id1 and upon downregulation of Id1 results in the 
reduction of breast cancer cell migration and invasion (Fong et al., 2003).   
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Figure 3: Id1 and Id3 expression in cancer cell lines and tissue samples: A, B. 
Id1 and Id3 expression in cancer cell lines including melanoma cell lines (n=61). 
Data used from cancer cell encyclopedia (CCLE). (C) Id3 expression in various 
cancer tissue samples from patients (The human protein atlas).   
 
The role of Id1 in breast cancer was clearer when it was found that Id1 expression 
inhibits the binding of p53 to PTEN which further results in the activation of canonical 
Wnt signalling pathway via AKT phosphorylation (Lee et al., 2009). The expression 
level of Id1 and Id3 are higher in prostate cancer tissue compared to the normal 
prostate tissue as well in prostate cancer cell lines. Silencing of Id1 and Id3 or Id3 
alone using siRNA significantly reduces the proliferation of prostate cancer cell lines. 
The data further indicates that Id1 and Id3 regulate p21 and p27 cell cycle inhibitor 
respectively in prostate cancer cell lines (Sharma et al., 2012). Knocking down Id1 
and Id3 in prostate cancer cell line shows reduced Tgf-β induced migration (Strong 
et al., 2013). Similarly, overexpression of Id3 in colorectal cancer cells affects the 
cell cycle and promotes cancer progression inhibiting p21. Here, Id3 was shown to 
be activated via AKT1/Smad5 which is the downstream target of S100A8/9 (Zhang 
et al., 2015). In non-small cell lung cancer (NSCLC), Id1 and Id3 co-expression have 
been associated with the poor overall survival of the patients and low response rate 
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(50%) to the treatment compared to (87%)  patients with no Id1-Id3 expression 
(Castanon et al., 2013). Besides, prominent research in the field of cancer 
mechanism has exposed the role of Id proteins as instrumental in the progression of 
several cancer types including gastric cancer, hepatocellular cancer and pancreatic 
cancer (Wang et al., 2004) (Sharma et al., 2016) (Kleeff et al., 1998). 
1.5.7 Id protein in cancer cell dedifferentiation 
 Many cancer types represent small sub-populations of cells which have the 
capability to initiate tumour and they show the phenotype similar to cells in 
embryonic development. Researchers have coined many terminologies like cancer 
stem cells or cancer-initiating cells to define these small sub-populations. For better 
comprehension I would call here these cells, dedifferentiated cells. The presence of 
cancer stem cells or dedifferentiated cells in cancer attributes aggressiveness and 
drug resistance. In order to study the role of genes involved in dedifferentiation, 
several models have been suggested. One of the prominent in vitro model is 3d cell 
culture. Very recently it was shown that Id4 is highly expressed in the melanoma 
spheres along with other genes related to development. Knocking down Id4 resulted 
in more differentiated phenotype and preventing the formation of spheroids (Peretz 
et al., 2015). Glioblastoma and colon cancer are other two cancer types where the 
role of Id protein in dedifferentiation have been well studied. Id1 expression in 
glioblastoma has been associated with metastasis through epithelial to 
mesenchymal (EMT) as well proliferation and invasion (Guo et al., 2013). On the 
other hand, a study using glioma mouse model reveals that high Id1 expression is 
required for the self-renewal but it doesn’t affect the tumorigenic potential (Barrett et 
al., 2012). However, in case of high-grade gliomas (HGG), a malignant glioma 
mouse model was created and when Id gene (Id1, Id2 and Id3) was deleted in only 
tumours and not the endothelial cells or tumour microenvironment resulted in tumour 
regression and extended survival due to rapid loss of glioma-initiating cells (GICs) 
from the perivascular tumour niche due to inhibition of RAP1GAP (Niola et al., 
2013). In colon cancer, double knock down of Id1-Id3 in colon cancer-initiating cells 
(CC-ICs) resulted in complete loss of tumour formation in xenografts. An 
immunohistochemical analysis determined that Id1-Id3 knockdown leads to induction 
of differentiation and reduction in micro vessel density (MVD). More importantly, 
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double knockdown of Id1-Id3 significantly reduced the sphere formation capacity and 
increased sensitivity to chemotherapy. Id1-Id3 double knockdown affect the tumour 
initiating potential by downregulating the cell cycle inhibitor p21 (O’Brien et al., 
2012). 
1.5.8 Id protein and drug resistance 
Resistance to therapy has been the predominant concern in most of the cancer 
patients getting the treatment. The efficacy of the drug is subdued due to resistance 
in many cases. Several studies have focused in order to determine the mechanisms 
behind the gain of resistance to certain drugs in cancer. The data accumulated from 
these studies has revealed that Id proteins play directly or indirectly a pivotal role 
during drug resistance. In prostate cancer, it was shown that interaction of Id1 and 
caveolin-1 enhances the process of EMT and reduces apoptosis induced by Taxol 
through activation of AKT pathway. Knocking down Id1 using siRNA makes the 
prostate cancer cells more sensitive to the Taxol treatment (Zhang et al., 2007) 
(Wong et al., 2008). Besides, B-cell leukemia-3 (Bcl-3), a proto-oncogene, has been 
also shown to regulate Id1 and Id2 expression in prostate cancer upon exposure to 
IL-6 which is responsible for inhibiting apoptosis and inducing resistance to 
chemotherapy (Ahlqvist et al., 2013). Id1 expression has also been associated with 
glioma-initiating cells and conferring resistance to therapies. Similarly, silencing of 
Id2 expression in glioma cells resulted in higher sensitivity to the antineoplastic drugs 
used for the treatment of brain tumours (Anido et al., 2010) (Zhao et al., 2015). 
Moreover, a comparison between tamoxifen-sensitive (TS) and tamoxifen-refractory 
(TR) breast cancer patients revealed that Id4 was hypomethylated in TR breast 
cancer (Zhang et al., 2015). In colorectal cancer, overexpression of leukaemia 
inhibitory factor (LIF) is responsible for the chemoresistance via negatively regulating 
p53. To achieve this, LIF induces STAT3 expression which transcriptionally activates 
Id1 which further upregulates MDM2 expression and MDM2 promotes the 
degradation of p53 protein (Yu et al., 2014). Collectively, these data highlights the 
involvement of Id proteins in cell survival and drug resistance in various cancer 
types.
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2. Aims of the project 
 
Melanoma cells show a high degree of heterogeneity and a sub-population of the 
tumour cells represent a dedifferentiated phenotype. Dedifferentiation in melanoma 
is attained by the reactivation of genes from neural crest origin. Reports from several 
studies suggest that dedifferentiation attributes aggressiveness to several cancers 
including melanoma. It is responsible for the tumour initiation, metastasis and more 
importantly for conferring resistance to the therapies. This study aims to find new 
marker for the dedifferentiation in melanoma and their role in melanoma 
pathogenesis. It might also help in the development of new strategies to eliminate 
melanoma.  
The specific aim of this study is: 
1. To identify genes that are expressed in neural crest cells, melanoma cell lines and 
are also upregulated in targeted therapy resistant cells. 
2. To investigate the role of candidate gene/s in melanoma proliferation and 
metastasis and to find the mechanism for its functioning. 
3. Finally, to examine the role of candidate gene/s in melanoma resistance to the 
targeted therapies. 
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3. Materials and Methods 
3.1 Materials 
3.1.1 Reagents and Kits 
Product     Company   Catalog   
Agarose NEEO Ultra Qualität   Carl Roth   2267.4 
Alamar Blue®     Invitrogen   DAL1100 
Amersham ECL prime western blotting  GE healthcare   RPN2232 
detection reagent      
Ammonium persulfate solution (APS)  Carl Roth   9592 
ARCTURUS PicoPure RNA   Life Technologies  KIT0204 
Isolation Kit 
Complete mini protease inhibitor cocktail Roche Diagnostics  04693159001 
Endofree plasmid maxi kit    Qiagen    12362 
High performance chemiluminescence film GE healthcare   28906836 
IBIDI Culture-Insert 500 µM   Ibidi    80209 
Immobilion PVDF membrane pore- 0.45µM Merck Millipore   IPVH00010 
Luminata Forte Western HRP substrate  Millipore   WBLUF0500  
Pierce BCA protein assay kit   Thermo scientific  23225 
PhosSTOP
TM
 Phosphatase inhibitor Cocktail Roche diagnostics  04906845001 
Precision Plus     Bio-Rad   161-0394 
RNase-Free Dnase set    Qiagen    79254 
RNeasy plus Mini kit    Qiagen    74136 
RevertAid First strand cDNA synthesis kit Thermo Scientific  K1622 
Skim milk powder    Flika Analytical   F7016605000 
SYBR Green PCR Master mix   Applied Biosystems  4309155 
TEMED      Carl Roth   2367.3 
Tween® 20     Applichem   A13890500 
TritonX-100     Carl Roth   3051.4 
X-treme GENE® 9 DNA transfection  Roche Diagnostics  06365787001 
Reagent 
 
3.1.2 Cell culture reagents 
 
Product     Company   Catalog 
 
2-Mercaptoethanol    Gibco® Life Technologies 31350010 
Ascorbic acid     Sigma Aldrich   1043003 
Blasticidine S     Sigma Aldrich   15205 
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Bone morphogenic protein 4 (BMP4)  Promokine   C-67313 
DMSO      Carl Roth   A994.2 
DMEM AQ media
TM
    Gibco® Life technologies 41965-039 
Fetal Calf Serum (FCS)    Biochrom   S0115 
Human melanocyte growth   Gibco® Life Technologies S002-5   
supplement (HMGS) 100x 
Lipofectamine® RNAiMAX transfection reagent Life Technologies  13778075 
Medium 254      Gibco® Life Technologies M254500 
Non-essential amino acids   Sigma-Aldrich   M7145 
Opti-MEM® I reduced serum medium  Gibco® Life Technologies 31985062 
PBS      Sigma-Aldrich   D8537 
Penicillin/Streptomycin    Sigma-Aldrich   P4333 
Puromycin      Carl Roth   240.1 
Trypan blue solution     Sigma-Aldrich   93595 
Trypsin      Sigma-Aldrich   T3924 
 
3.1.3 Human melanoma cell lines 
  
Cell Line  Source  Disease   Mutation 
A375   ATCC   Malignant Melanoma  BRAF V600E 
C32   ATCC   Melanoma, amelanotic  BRAF V600E 
HT144   ATCC   Malignant Melanoma  BRAF V600E 
MeWo   ATCC   Malignant Melanoma  WT 
Skmel 23  ATCC   Melanoma   WT 
Skmel 28  ATCC   Malignant Melanoma  BRAF V600E 
Skmel 30  DKMZ Leibniz Inst. Melanoma   NRAS Q61R 
Skmel 103  CNIO Madrid  Melanoma   NRAS Q61R 
Skmel 147  CNIO Madrid  Melanoma   NRAS Q61R 
Skmel 173  CNIO Madrid  Melanoma   WT 
WM266-4  ATCC   Melanoma   BRAF V600D 
 
3.1.4 Antibodies 
 
Product  Source  Company   Catalog 
 
Anti-GAPDH  Rabbit   Cell signalling   CST2118 
Anti-Id1   Rabbit   Cal-bio reagent   M085 
Anti-Id3   Rabbit   Cal-bio reagent   M100 
Anti-MITF  Mouse   Abcam    ab80651 
Anti-SOX10  Mouse   Abcam    ab181466 
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3.1.5 Small molecule inhibitors 
 
Product    Company    Catalog 
 
Vemurafenib (PLX4032)  Selleckchem    S1267 
Trametinib (GSK1120212)  Selleckchem    S2673 
Dabrafenib (GSK2118436)  Selleckchem    S2807 
 
3.1.6 Buffers, Solution and Gels 
 
Transfer buffer (pH 8.3)    Running buffer (pH8.3)       TBS 10X (pH 7.6) 
25mM Glycine         25mM Glycine         150mM NaCl 
190mM Tris 190mM Tris                   50mM Tris 
20% SDS 0.1% SDS           dH2O 
20% methanol dH2O  
dH2O 
 
 
Washing buffer (TBST) Washing buffer (PBST) Blocking buffer (milk) 
0.02% Tween® 20  0.02% Tween® 20  5% Skim milk powder 
1X TBS    PBS    Washing buffer (PBS or TBS) 
 
Cell lysis buffer for protein isolation 
1X PhosphoStop 
1X Complete mini protease inhibitor cocktail  
1% Triton-X in TBS 
 
10% SDS separating Gel (10ml)  15% SDS separating Gel (10ml) 
H2O  (4 ml)     H2O  (2.3 ml)  
30% Acrylamide mix (3.3)   30% Acrylamide mix (5.0) 
1,5 M Tris (pH 8.8) (2.5ml)   1,5 M Tris (pH 8.8) (2.5ml) 
10% SDS (0.1 ml)    10% SDS (0.1 ml) 
10% APS (0.1 ml)    10% APS (0.1 ml) 
TEMED (0.004ml)    TEMED (0.004ml) 
 
Stacking Gel (10ml) 
H 2 O (6.8 ml) 
30% Acrylamide mix (1.7 ml) 
1,0 M Tris (pH 6.8) (1.25 ml) 
10% SDS (0.1 ml) 
10% APS (0.1 ml) 
TEMED (0.01 ml) 
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3.1.7 Devices 
 
Product Description     Company    
 
AB 7500 Real-Time PCR machine   Applied Biosciences  
Classic E.O.S. Developer     AGFA Mortsel, Belgium 
Nanodrop Spectophotometer ND-1000   Peqlab Biotechnologie GmbH  
Nikon Eclipse Ti Fluorescence microscope  Nikon  
Nikon Eclipse TS100      Nikon  
Tecan infinite F200 PRO    Tecan  
 
3.1.8 Software 
 
Analysis Software    Source 
7500 Software v2.0.5    Applied Biosystem 
ApE      M. Wayne Davis (Open Source)  
BD FACSDivaTM     Biolegend 
Chipster     Chipster Open source 
FlowJo 7.2.2     FlowJo 
Graphpad Prism    Graphpad Prism 
i control 1.10     TECAN 
Image J     NIH 
Mendeley     Mendeley 
NIS-Element     Nikon 
T-scratch     CSElab  
 
3.1.9 Online databases 
 
Name      Website 
cBioportal     http://www.cbioportal.org  
Cancer Cell Line Encyclopedia   http://www.broadinstitute.org/ccle 
GEO dataset     https://www.ncbi.nlm.nih.gov/gds/?term= 
The Human Protein atlas   http://www.proteinatlas.org/ 
TRED      https://cb.utdallas.edu/cgi-bin/TRED/ 
Transcription factor binding sites  http://www.sabiosciences.com/ 
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3.1.10 Plasmids  
 
Product     Company    
 
shRNA against human Id3 (Id3-shRNA)  Sigma-Aldrich 
Non-targeting shRNA (NT-shRNA)  Sigma-Aldrich 
pLX304 (Empty vector)    Addgene 
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3.2 Methods 
3.2.1 Cell culture and cell lines 
The human melanoma cell lines (A375, C32, HT144, MeWO, Skmel 28, Skmel 23, 
Skmel 30, Skmel 103, Skmel 147, Skmel 173, and WM266-4) were cultured in 
DMEM (Gibco, Life Technologies) with 10% FBS (Biochrom), 0.1mM β-
mercapthoethanol (Gibco, Life Technologies), 1% non-essential amino acids (NEAA) 
and 1% Pen/Strep (Sigma-Aldrich).  
Normal human melanocytes (NHM) isolated from donor foreskins according to the 
ethical regulation (Ethics committee II, University Medical Centre Mannheim, 
Germany) and were cultivated in medium 254 (Gibco, Life Technologies) 
supplemented with 100x human melanocyte growth supplement (HMGS) (Gibco, Life 
Technologies). Human neural crest cells were generated as described previously 
(Larribere L et al 2015) in the protocol for hiPSC-derived melanocyte differentiation. 
All cell lines were cultured in humidified incubator at 370C and 5% CO2. Cell lines 
were sub-cultured every 3-5 days when they were about 80% confluent. 
 
3.2.2 Lentiviral particle production and transduction 
Lentivirus particles were produced in HEK293T cells. HEK 293T cells were 
approximately 60% confluent on the day of transfection. For one T-75 flask, 770µl of 
DMEM medium (without FCS) was mixed with 50µl of X-tremeGENE® (Roche) and 
incubated for 5 min at room temperature. Subsequently, the plasmid with the gene of 
interest (11µg) along with packaging plasmids VSV-G (5.5µg) and Δ8.9 (8.25µg) was 
mixed in the DMEM and X-treme GENE® solution. The mixture was incubated for 30 
min at room temperature and then added to HEK293T producer cells. After 12h, the 
medium was changed. Virus supernatant was collected after 24h, 36h and 48h. The 
collected supernatant was filtered through a 0.45μm PVDF filter and concentrated by 
centrifugation for 5h 21,000g at 4°C in a high-speed centrifuge. The virus pellet was 
re-suspended in 100µl PBS aliquoted and stored at -80°C. The concentrated virus 
was used to infect the cells. The virus production was done in a Biosafety level II 
laboratory, according to the safety instruction. 
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3.2.3 Transduction with lentiviral particles 
Cells were seeded in 6 well plates with 50-60% confluency and incubated for 16-18h 
in humidified incubator at 370C and 5% CO2. Fresh medium with virus (500µl-1ml 
supernatant or 5µl concentrated virus) was added to the cells. Cells were again 
transduced after 24h as described above. After 48h transduction was stopped and at 
least 3 times cells were washed with PBS. The Normal fresh medium was added to 
the cells and grown for at least 24h to let them recover before selection.   
 
3.2.4 Antibiotic selection 
Cell lines with Id1 and Id3 shRNA were selected by using puromycin (0.5-0.8µg/ml) 
and cell lines with Id1 and Id3 overexpression vector was selected using blasticidin 
(5-8µg/ml) for 4-6 days.   
 
3.2.5 RNA isolation and cDNA synthesis 
Total RNA isolation was done using RNeasy Mini kit (Qiagen) according to the 
manufacturer’s protocol. The RNA was treated with DNase I on the column. RNA 
concentration and quality were measured by NanoDrop ND1000 spectrophotometer. 
cDNA was synthesised using the Revert Aid First Strand cDNA synthesis kit 
(Thermo scientific) according to the manufacturer’s protocol.  
 
3.2.6 qPCR 
Quantitative real-time PCR (qPCR) was performed using SYBR Green (Applied 
Biosystems, Life technologies) on a 7500 real-time PCR system (Applied 
Biosystems, Life technologies).In all experiments, 18s was used as the 
housekeeping gene and the values were normalised to it. Relative gene expressions 
were quantified by calculating (∆∆Ct). Primers used are as follow: 
18s F: GAGGATGAGGTGGAACGTGT 
18Sr: TCTTCAGTCGCTCCAGGTCT 
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Id1 F: TTCAGCCAGTCGCCAAGAAT 
Id1 R: CCACGCTCTGCTCAGACA 
Id3 F: GGAGCTTTTGCCACTGACTC 
Id3 R: TTCAGGCCACAAGTTCACAG 
SOX10 F: GGCTTTCTGTCTGGCTCACT  
SOX10 R: TAGAGGGTCATTCCTGGGGG 
MITF F: GCTCACAGCGTGTATTTTTCC 
MITF R: TCTCTTTGGCCAGTGCTCTT 
 
3.2.7 Western Blot 
Cells were harvested and washed with PBS. Protein was extracted from the cells by 
using complete mini lysis buffer (Roche) with 1% Triton-X-100. The protein 
concentration was determined using the Pierce BCA protein assay kit (Thermo 
scientific). Proteins were resolved on SDS-PAGE and transferred onto PVDF 
membranes (Merck Millipore). Later the membrane was probed with primary 
antibodies and then with HRP conjugated secondary antibody. The bands were 
visualised using Luminata Forte western HRP substrate (Merck Millipore) according 
to manufacturer’s protocol. The band intensities were quantified using ImageJ 
software (Fiji). The primary antibodies used are as follow: 
Id1(cal bio), Id3(Calbio), SOX10 (Abcam), MITF (Abcam), GAPDH (Cell signalling).   
 
3.2.8 Cell proliferation and cell cycle analysis 
Cell proliferation was measured using Alamar blue (Invitrogen). Approximately 2500 
or 5000 cells were seeded in triplicates in a 96 well plate. After 24 hours Alamar blue 
(10% of the medium) was added and the plates were incubated for 4 hours at 370C. 
Fluorescence was measured with excitation wavelength at 530-560 nm and emission 
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wavelength at 590 nm using the Tecan Infinite 200 Pro plate reader. Proliferation 
was measured for 4 to 5 days. 
Cells were seeded (4-6x 105) in 6 well plates in triplicates and incubated at 370C for 
18-24 hours. After that cells were washed withPBS, trypsinized and collected in 
tubes. The pellets were resuspended in ice-cold PBS and fixed with pre-cooled 70% 
ethanol. Cells were then washed with ice-cold PBS and treated with RNase for 30 
min at 370C.  Propidium iodide (50µg/ml) was used to stain the cellular DNA. Cell 
cycle stages were analysed in Flowcytometer Canto (Becton-Dickson).  
 
3.2.9 Cell viability 
 Approximately 2500 cells were seeded in a 96 well plates. After 16-18 hours desired 
concentrations of Vemurafenib or Trametinib was added to the cells. After every 24 
hours up to 5-6 days, cell viability was measured using Alamar blue as described 
above. Approximately 1X105 cells were seeded in 6 well plates. After 16-18 hours 
desired concentration of Vemurafenib and Trametinib was added and incubated at 
370C for 72 hours. After 72 hours cells were trypsinized and washed with PBS. Total 
RNA was isolated and cDNA was synthesised as described previously. This 
experiment was performed in triplicates with DMSO as a control. 
 
3.2.10 Migration assay 
Cell migration was studied using Ibidi culture inserts. Approximately 70000 Cells 
were seeded inside the inserts and were starved overnight. The inserts were 
removed and cell migration was observed every 4 hours over 24 to 28 hours. 
TScratch software was used for the quantitative analysis of the data. 
 
3.2.11 Immunohistochemistry  
To perform immunostaing, 4µm sections of formalin-fixed paraffin-embedded tissue 
sections were stained with antibodies against Id1 and Id3 as per the manufacturer’s 
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instruction. All analyses involving human melanoma tissues were carried out 
according to the principles of the Declaration of Helsinki and were approved by the 
medical Ethics Committee of the Medical Faculty Mannheim, University of 
Heidelberg.  
 
3.2.12 Microarray expression analysis 
Total RNA was isolated from primary melanocytes (NHM), human neural crest cells 
and melanoma cell lines A375 and C32 Vemurafenib treated and DMSO control) and 
purified using RNeasy kit (Qiagen). Total RNA samples were submitted for analysis 
to the DKFZ Genomics and Proteomics Core Facility by using HumanHT-12 v4 from 
ILLUMINA (Santa Clara, CA, USA). Bayes test was used as test of significance to 
the bead expression values of the two groups of interest. List of differentially 
expressed genes were selected using P-value threshold of 0.05 and log2-
expression. 
 
3.2.13 Bacterial transformation and plasmid isolation 
For transformation, DH5α competent Escheria Coli (E.coli) bacteria were used. 
Bacteria cells were first thawed on ice and then 100μL of competent cells were 
mixed with 5μL of the ligation mix in a pre-chilled eppendorf tube.  The samples were 
mixed by pipetting and incubated on ice for 30 min. The mix was subjected to heat 
shock for 90 sec in a 42°C water bath and incubated for 5 min on ice. Subsequently, 
500μL of SOC-medium was added to each sample and again incubated for 1 hour at 
37°C on a thermos-mixer with shaking at 400 rpm. After incubation, the samples 
were centrifuged at 6,000 rpm for 3 min, 450μL of the supernatant was removed and 
the pellet was resuspended. The transformed bacteria were streaked onto LB-agar 
plates with ampicillin (100μg/ml) and were left to incubate at 37°C overnight 
(approximately 18 hours) upside-down for colony formation. Next day colonies were 
picked and incubated in 5ml LB medium with 100μg/ml ampicillin at 37°C overnight. 
The plasmid was isolated as per manufacturer’s guide using mini-preparation kit 
(Qiagen). Restriction digestion was performed to determine the correct insert and 
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vector. Next, I incubated the bacteria with the specific plasmid in 200ml LB medium 
containing 100μg/ml ampicillin at 37°C overnight. Thereafter the Qiagen Maxi kit was 
used to isolate the plasmid DNA. Plasmid DNA was precipitated using isopropanol 
and ethanol. The DNA pellet was air-dried and resuspended in TE buffer. Plasmid 
DNA concentration and quality was checked using Nanodrop ND-1000.    
 
3.2.14 Statistical analysis 
The software GraphPad Prims version 5.00 was used for statistical analysis. 
Statistical significance using two-tailed paired and unpaired t-test was determined if 
p < 0.05 (*), <0.01 (**) and 0.005 (***). 
 
3.2.15 Software Used 
T scratch software was used to analyse the migration assay. To analyse the 
microarray data chipster was used. 
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4. Results 
 
4.1 Identification of genes regulating dedifferentiation in Melanoma     
                             
Metastatic melanoma is a very heterogeneous cell population and during its 
development it reminiscences phenotype which is similar to its embryonic origin. This 
phenotype switch in melanoma has been considered to be responsible for resistance 
to several therapies (Landsberg et al.,  2012) (Roesch et al., 2016). To accomplish 
this, melanoma cells reactivates genes which were switched off during the process 
of differentiation. In order to trace the genes which are primarily involved in this 
process, induced pluripotent stem cells (iPSCs) in our lab was generated. Later, in 
controlled conditions, the iPSCs were differentiated into melanocytes via neural crest 
stage. Also, to have an insight into their role in drug resistance I treated the BRAF 
mutated melanoma cell lines (A375, HT144, Skmel 28 and WM266-4) with BRAF-
inhibitor, vemurafenib. These cell lines were treated with a higher dose (3µM) of 
vemurafenib for 6h, 24h, 48h and 72h. Cells were treated with DMSO as a control for 
same time points. After each time points, the cells were trypsinized and harvested for 
RNA extraction (Figure 4A). Next, the whole genome expression of melanoma cells 
treated with vemurafenib (72h), respective DMSO-treated control melanoma cell 
lines, more differentiated normal human melanocytes (NHM) and less differentiated 
neural crest cells derived from iPSCs was compared. Total RNA in triplicates were 
used and the microarray data were analysed using the chipster software. An 
unsupervised hierarchical clustering showed two major clusters. The more 
differentiated cells i.e. NHM and DMSO-treated melanoma cell lines clustered 
together whereas the second cluster contained vemurafenib-treated melanoma cell 
lines with less differentiated neural crest cells (Figure 4B). Therefore, from the 
clustering data, it could be shown that the vemurafenib-treated cell lines are more 
similar to the neural crest cells or dedifferentiated. Moreover, it was also found that 
Id gene family- Id1, Id2 and Id3 were upregulated (log2-fold change ranging from 1 
to 2.5)  along with pluripotency marker genes like LIN28, POU5F1, SOX2, DNMT3B, 
ALPL as well as a multipotency marker gene, TWIST1, in the dedifferentiated group 
of cells compared to the NHM and DMSO-treated group. Similarly, the melanocyte or 
differentiation markers like DCT, MC1R, MITF, MELANA, SOX10, TYR and TYRP1 
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were down-regulated (log2-fold change ranging from -1 to -3.3) in the vemurafenib-
treated melanoma cells and the neural crest group compared to the NHM and 
DMSO-treated group (Figure 4C). 
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Figure 4: Id3 expression is upregulated during adaptive vemurafenib 
resistance in human melanoma cell lines. A. Schematic representation of human 
melanoma cell lines treatment with vemurafenib (3µM, 72h) followed by gene 
expression analysis. B. Heat map representation of unsupervised hierarchical 
clustering of differentially expressed genes in neural crest cells (NC), normal human 
melanocytes (NHM) and melanoma cell lines (A375 and C32) treated with 
vemurafenib (V) or with DMSO (D). C. This panel shows that the pluripotency or 
multipotency marker genes along with Id genes are upregulated and differentiation 
(melanocytic) marker genes are downregulated. D. Id3 mRNA expression in human 
melanoma cell lines treated with vemurafenib for 6h, 24h, 48 h and 72h. 18s was 
used as an endogenous expression control and DMSO treated cells were used as 
reference sample. The qPCR results shown here are mean of + SD of biological 
triplicates. *P<0.05, **P<0.01, ***P<0.001 and ns = not significant.  
 
Additionally, the AXL expression was found to be upregulated in the vemurafenib-
treated cell lines, which is in accordance with the recent report describing low 
MITF/AXL expression ratio during early drug resistance in melanoma (Muller et al., 
2014). It was further demonstrated through qPCR that the Id3 expression was 
upregulated after treatment with vemurafenib. Here it was observed that a significant 
increase in Id3 expression starts as early as 6 hours after the treatment with 
vemurafenib in 3 melanoma cell lines (C32, A375 and WM266-4) and remained 
higher after 24 hours, 48 hours and 72 hours in all the 5 cell lines (A375, C32, 
WM266-4, Skmel 28 and HT144) (Figure 4D). More interestingly, upregulation of Id3 
in NRAS mutated cell lines (Skmel 30, Skmel 103 and Skmel 147) was detected 
after treatment with the MEK inhibitor (trametinib) at different time points 
(Supplementary Figure 2). Additionally, upregulation of Id3 in three BRAF mutated 
cell lines (A375, C32 and Skmel28) after treatment with BRAF inhibitors 
(Vemurafenib and Dabrafenib), MEK inhibitor (Trametinib) or in combination 
(Vem+Tra, Dab+Tra) was found (Supplementary Figure 3). These data suggests 
the potential involvement of Id3 in drug resistance is not BRAF- specific. 
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4.2 Expression of Id1 and Id3 in melanoma  
To better understand the role of Id genes (mainly Id1 and Id3) in melanoma 
development, the human melanoma cell lines according to their Id1 and Id3 
expression were characterised. For this, the qPCR and western blot techniques were 
used to show their mRNA and protein expression level in different human melanoma 
cell lines. This human melanoma cell panel can be divided into BRAF mutated 
(A375. C32, HT144, Skmel 28 and WM266-4), NRAS mutated (Skmel 30, Skmel 103 
and Skmel 147) and BRAF/NRAS wild types (Skmel 23, Skmel 173 and MeWo). 
From the mRNA expression, it was shown that most of the cell lines express higher 
Id1 and Id3 compared to the NHM (Figure 5A, B). 18s was used as the house-
keeping gene. Similarly, the protein expression of Id1 and Id3 in most of these cell 
lines were higher in comparison to the NHM. Interestingly, from the results, no 
correlation between the Id1 and Id3 expression and their mutational status was 
established (Figure 5C, D) 
A.       B. 
 
 
 
 
 
C.          D. 
 
 
 
Figure 5: Id1 and Id3 expression in melanoma cell lines. A, B. mRNA expression 
of Id1 and Id3 in normal human melanocyte (NHM) and human melanoma cell lines. 
18s was used as endogenous control and normal human melanocytes (NHM) was 
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used as the reference. The qPCR results showed here are mean + SD of biological 
triplicates. Protein expression of Id1 (C) and Id3 (D) in NHM and human melanoma 
cell lines. 
Further, immunohistochemistry (IHC) technique was used to check the expression of 
Id1 and Id3 in tissue samples. For this I prepared, fixed and stained using Id1 and 
Id3 antibody primary melanoma, metastatic melanoma and dermal nevus tissue 
samples derived from patients. The staining results showed that Id1 and Id3 are 
highly expressed in both primary and metastatic melanoma tissues as well as in 
dermal nevus (Figure 6A, B).  
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Figure 6: Id1 and Id3 expression in human melanoma patient tissue samples. 
A. The top panel shows the expression of Id1 in the primary, metastatic melanoma 
and dermal nevus. B. The bottom panel shows the Id3 expression in the primary, 
metastatic melanoma and dermal nevus. Images represent 4X and 20X 
magnification. No secondary antibody staining was used as a negative control. 
 
4.3 Id3 Knock down in melanoma cell lines reduces cellular 
migration 
In order to understand the role of Id3 in melanoma cell migration and proliferation, 
Id3 was stably knocked down using short-hairpin RNA (shRNA). The shRNA against 
Id3 was selected from the RNAi consortium which has 100% Specificity-Defining 
Region (SDR) in the coding sequence of Id3. Subsequently, I chose 5 cell lines with 
different mutational status and high Id3 expression i.e. A375 (V600E), HT144 
(V600E), Skmel 28 (V600E), Skmel 147 (NRASQ61L) and MeWo (WT). Stable 
transfection of Id3-shRNA was performed using the lentiviral particles. Later, the 
cells were selected using puromycin and allowed to grow for few days. 
The knocking down efficiency of Id3 was validated through western blot technique. It 
was found that the expression of Id3 was significantly suppressed in all the 5 cell 
lines compared to their respective controls with non-targeting shRNA (NT) (Figure 
7A). From the Image quantification data, it was determined that in 4 (A375, HT144, 
MeWo and Skmel 147) out of 5 cell lines the Id3 expression was more than 80% 
reduced, whereas, in  Skmel 28 there was more than 60% reduction in the 
expression (Figure 7B). 
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Figure 7: Id3 knockdown in melanoma cell lines. A. Id3 was knockdown in Skmel 
28, HT144, MeWo Skmel 147 and A375 cell lines using shRNA against Id3. Id3 
protein expression was evaluated using western blot after the knockdown. GAPDH 
was used as a loading control. B. Percentage of Id3 protein expression was 
estimated using image J. 
 
It is well-documented that Id proteins play a significant role in inhibiting differentiation 
and promote proliferation (Lasorella A et al., 2014). Therefore, the effect of Id3 
knockdown on proliferation in the melanoma cell lines was first examined. Alamar 
blue assay (Invitrogen) was performed to study the proliferation. For this, the cells 
with Id3 shRNA and their controls were seeded and measured their growth after 
every 24 hours up to 5 days.  The results from this assay displayed that there was no 
significant difference in proliferation between the cell lines with Id3 shRNA and their 
non-targeting controls (Figure 8A). This observation was further verified through cell 
cycle analysis using flow cytometry technique. In this experiment, the cells were 
fixed in 70% ethanol and then stained them using propidium iodide (PI). The flow 
cytometry data analysis gave the percentage of cells in different cell cycle stages 
(G0/G1, S and G2/M). Here, no difference was observed in the percentage of cells in 
different cell cycle stages between Id3 knockdown cell lines and their respective 
controls (Figure 9A). Hence, the Alamar blue assay and cell cycle analysis 
confirmed that there was no effect on proliferation or cell cycle after knocking down 
Id3 alone in melanoma cell lines. 
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Figure 8: Id3 knockdown in melanoma cell lines does not affect proliferation: 
A. Alamar blue assay was used to detect the difference in cell proliferation between 
Id3 knockdown and control cell lines from day 1 to day 5 (A375, Skmel 28, HT144, 
Skmel 147 and MeWo). The cell proliferation results show the mean + SD of 
biological triplicates.  
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B. 
 
 
 
 
 
Figure 9: Id3 Knockdown does not alter the cell cycle. A, B. Analysis of cell cycle 
stages by flow cytometry of A375 and Skmel 28 with Id3 knockdown compared to the 
non-targeting control. Cells stained with PI were gated based on their DNA content 
(left panel) and each cell cycle stages were quantified (right panel). The cell cycle 
results show the mean + SD of biological triplicates.  
 
The earlier report suggests the involvement of Id3 in various cancer metastasis but 
there is little known about its role in melanoma metastasis. Therefore, I thought to 
investigate its function during melanoma migration (Tsuchiya T et al., 2005) (Shuno 
Y et al., 2010). For this, a scratch like assay was performed using ibidi chambers or 
inserts made up of biocompatible silicone. These inserts help in making a gap of 
approximately 500 µm in the monolayer of the cells and the closing of the gap due to 
cell migration was recorded over a period of time. The entire melanoma cell lines 
knockdown for Id3 and their corresponding controls were seeded using these inserts. 
After the insert was taken out, I took pictures after every four hours till the time gap 
was completely closed. The images were analysed using the T-scratch software. It 
was found that after knocking down Id3 in cell lines A375, Skmel 28 and Skmel 147 
the migration was significantly impaired. A375, Skmel 28 and Skmel 147 Id3 
Knockdown cells migrate approximately 20-30 % slower compared to their 
respective controls (Figure 10A, B). Whereas in HT144 and MeWo cell lines, a trend 
in the same direction was observed but the results were not significant (Data not 
shown here). These findings suggest that silencing of Id3 alone in melanoma cell 
lines can impair its migration in vitro.  
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A. 
 
 
 
B. 
 
 
 
Figure 10: Id3 Knockdown in melanoma cells reduces cell migration. A. 
Representative images of cell migration assay. Migration of A375 and Skmel 28 cell 
line with Id3 shRNA (A375 Id3 Kd, Skmel 28 Id3 Kd) and non-targeting shRNA (A375 
NT, Skmel 28 Id3 Kd) was measured at 0 hour and 8 hours after creation of the gap. 
Skmel 147 Id3 Kd and Skmel 147 NT cell migration was measured after 24 hours. B. 
The bottom panel represents the percentage migration of A375, Skmel 28 and Skmel 
147 with Id3 shRNA and non-targeting shRNA. The graph represents the mean + SD 
of biological triplicates. *P<0.05, **P<0.01, ***P<0.001 and ns = not significant. 
 
4.4 Id3 overexpression in WM266-4 increases cellular migration 
After studying Id3 loss of function, Id3 gain of function in melanoma cells were 
studied. For this, I first chose a human melanoma cell line (WM266-4) which has 
very low level of endogenous Id3 expression (Figure 5B, D). Next, Id3 coding 
sequence was cloned in a lentiviral vector (PLX304). The cloning of Id3 was 
validated by restriction digestion and sequencing. Thereafter, Id3 overexpressing 
WM266-4 (WM266-4 Id3) cell line was generated and selected using blasticidin. The 
overexpression of Id3 in WM266-4 was confirmed using qPCR and western blot 
technique. WM266-4 with Id3 overexpressing vector showed an increase of Id3 
mRNA by 1000 folds compared to the empty vector control (WM266-4 EV) (Figure 
11A). Equally, the western blot also showed a tremendous increase in the protein 
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expression of Id3 in WM266-4 cell line with Id3 overexpressing vector compared to 
its control (Figure 11B). 
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Figure 11: Id3 overexpression in WM266-4 increases cellular migration. A. 
mRNA expression of Id3 in WM266-4 after transfection with Id3 expressing vector. 
18s was used as an endogenous control and WM266-4 with empty vector was used 
as the reference. The qPCR results showed here are mean + SD of biological 
triplicates. B. western blot data shows the Id3 protein expression in WM266-4 empty 
vector (WM266-4 EV) and WM266-4 Id3 overexpressing vector. C. Alamar blue 
assay was used to detect the difference in cell proliferation between WM266-4 Id3 
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overexpression and control cell lines from day 1 to day 5 (A375, Smel28, HT144, 
Skmel 147 and MeWo). C. Representative image of cell migration assay of WM266-
4 Id3 and empty vector control (WM266-4 EV). E. Graph represents the percentage 
migration of WM266-4 Id3 and empty vector control (WM266-4 EV).  The graph 
show the mean + SD of biological triplicates. *P<0.05, **P<0.01, ***P<0.001 and ns 
= not significant. 
 
To further understand if Id3 overexpression would affect the proliferation in WM266-
4, Alamar blue assay was performed and analysed the cell cycle in Id3 
overexpressing and control cells. Alamar blue assay results showed that there was 
no significant difference in the proliferation rate of Id3 overexpressing WM266-4 
compared to the empty vector control (Figure 11C). For cell cycle analysis, the cells 
were fixed with 70% ethanol and stained them with propidium iodide (PI). The flow 
cytometry data confirmed that there was also no difference in the percentage of cells 
in different cell cycle stages between WM266-4 Id3 and WM266-4 EV (Figure 12A). 
This result was in accordance with the previous knockdown results which showed 
that Id3 alone cannot affect the proliferation of melanoma cells. 
Now I wanted to check if the Id3 overexpression in WM266-4 cell line affects the cell 
migration or not. Again, the scratch like assay using ibidi chambers/inserts was 
performed. In figure 11D & E, it is evident that Id3 overexpression in WM266-4 
increases the migration rate by approximately 20% compared to the empty vector 
control. These findings highlight that Id3 plays a critical role in melanoma migration. 
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A. 
 
 
 
 
 
Figure 12: Id3 overexpression doesn’t alter the cell cycle. A. Analysis of cell 
cycle stages by flow cytometry of WM266-4 with Id3 overexpressing vector 
compared to the empty vector control. Cells stained with propidium iodide were 
gated based on their DNA content (left panel) and each cell cycle stages were 
quantified (right panel). 
 
4.5 Id3 expression in melanoma cells controls SOX10 expression 
To determine the underlying molecular mechanism behind Id3 influencing the 
melanoma cell migration, a large set of genes associated with melanoma migration 
were screened and checked the basal protein expression of some of these genes 
(Supplementary Figure 4). The screening result showed that the expression of Id3 
in 5 melanoma cell lines is significantly inversely correlated to the SOX10 expression 
(Figure 13D, left panel).  Moreover, MITF which is the downstream target of SOX10 
was also found to be inversely correlated to Id3 expression in the melanoma cell 
panel (Figure 13D, right panel). This inverse correlation was further confirmed from 
the human metastatic melanoma database. A significant inverse correlation exists 
between Id3 and SOX10/MITF in 52 metastatic melanoma patients sample (Figure 
10 E). Another important melanoma patient database, the cancer genome atlas 
(TCGA), also demonstrated an inverse correlation between Id3 and MITF by RNA 
sequencing results (Akbani et al., 2015).  
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Figure 13: Id3 knockdown or overexpression regulates SOX10 and MITF 
expression in melanoma cell lines. A. Quantitative real-time PCR analysis of 
SOX10 expression in Id3 knockdown melanoma cell lines (A375, HT144, MeWo, 
Skmel28 NT, Skmel 147). B. Quantitative real-time PCR analysis of MITF expression 
in Id3 knockdown melanoma cell lines (A375, HT144, MeWo, Skmel28 NT, Skmel 
147). 18s was used as endogenous control and cell lines with non-targeting shRNA 
(NT) were used as reference control. C. qPCR analysis of SOX10 expression in 
WM266-4 Id3 overexpressing cell line. 18s was used as endogenous control and 
WM266-4 with empty vector was used as a reference. The qPCR results shown here 
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SOX10 gene promoter  
transcription starting site 
are mean of + SD of biological triplicates. D. Protein expression of Id3 in melanoma 
cell lines is inversely correlated to SOX10 and MITF. E. mRNA expression of Id3 in 
metastatic melanoma patients is inversely correlated to SOX10 (left panel) and MITF 
(right panel) (GEO dataset- GDS3966). *P<0.05, **P<0.01, ***P<0.001 and ns = not 
significant. (Spearman correlation =r) 
 
Finally, the expression of SOX10 and MITF in Id3 knockdown and overexpressing 
cell lines was examined. Indeed, the expression of SOX10 was higher in cell lines 
(A375, HT144, MeWo, Skmel28 and Skmel147) with Id3 knockdown compared to 
the control cell lines (Figure 13A). Whereas its expression is almost reduced by 50% 
in WM266-4 with Id3 overexpression compared to WM266-4 with empty vector 
(Figure 13 C). Additionally, the qPCR data validated 3-5 fold increase in the mRNA 
expression of MITF in 3 out of 5 Id3 knockdown cell lines (Figure 13 B).  
A.                                                                  B. 
    
       
 
 
 
 
 
 
 
Figure 14: Probable E47 binding site on SOX10 promoter sequence. A. Two E47 
binding sites (red box) on SOX10 promoter sequence predicted using Qiagen 
prediction tool. B. Transcriptional Regulatory Element Database (TRED) shows three 
E47 binding sites on SOX10 promoter sequence. 
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To better understand the correlation between Id3 and SOX10 I did some in silico 
search. For this, I looked for the transcription factors that regulate SOX10 
expression. Using the prediction tool from Qiagen for the transcription factor binding 
site it was found that SOX10 has an E47 binding site in its promoter site (Figure 
14A).  This data was further validated using Transcriptional Regulatory Element 
Database (TRED) where three CANNTG sequence in the SOX10 promoter 
sequence was found (Figure 14B). It has been well documented that Id3 negatively 
regulates E47 by heterodimerizing and E47 mainly binds to the E- box motif 
(CANNTG) in the promoter region. Above findings suggest that Id3 could regulate 
the SOX10 expression by preventing E47 from binding to the SOX10 promoter.  
 
4.6 Id3 Knockdown sensitizes melanoma cells to the targeted 
therapy. 
In order to verify the effect of vemurafenib or trametinib on Id3 knockdown or 
overexpressing melanoma cells, the cell viability assay was conducted. For this, the 
BRAF mutated cell lines with different concentration (0.001, 0.01, 0.1, 1 and 10µM) 
of BRAF inhibitor (Vemurafenib) and the NRAS mutated cell line with MEK-inhibitor 
(Trametinib) were treated. The cell viability was tested using Alamar blue. It was 
found that Id3 knockdown cell line, A375, after 48 hours of treatment showed greater 
sensitivity to the vemurafenib compared to the non-targeting control. Similarly, Id3 
knockdown cell line Skmel 28 and HT144 were more sensitive to vemurafenib after 
96 hours of treatment in comparison to their non-targeting controls. Interestingly, 
Skmel 147 Id3 knockdown cell line were more sensitivity to the trametinib after 96 
hours compared to the Skmel 147 non-targeting cell line (Figure 15A). Lastly, it was 
also found that upon Id3 overexpression in WM266-4 the cell survival rate after 
treatment with vemurafenib was increased significantly compared to the WM266-4 
cells with empty vector (Figure 15B).  These results indicate that Id3 expression in 
melanoma cells have profound effect during tumour progression and drug 
resistance.  
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A. 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
Figure 15: Id3 expression in melanoma cell lines provides resistance to the 
targeted therapy. A. The graph represents the effect of vemurafenib treatment 
(0.01-10 μM) after 48 hours (A375) or 96 hours (HT144, SKmel 28 and Skmel 
147) on the viability of Id3 knockdown or control cell lines, assessed by Alamar 
blue staining. The results are shown as mean + SD of biological triplicates. B. 
The graph represents the effect of vemurafenib treatment (0.01-10 μM) after 48 
hours (WM266-4) on Id3 overexpressing cell lines viability. The results are shown 
as mean + SD of biological triplicates. *P<0.05, **P<0.01, ***P<0.001 and ns = 
not significant. 
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5. Discussion 
Currently, different approaches have been involved in the treatment of melanoma 
patients as melanoma tumour displays numerous complexities at genetic as well as 
at immune level. The new treatments exhibit remarkable efficacy but resistance 
developed in patients restricts the benefits from these approaches. To identify the 
mechanism behind the gain of resistance, different theories and research models 
have been presented. A majority of publication supports that the resistance shown 
by melanoma patients, especially to the targeted therapies, is due to 
dedifferentiation. Like in other cancer types, it has been found that tumour cells in 
melanoma patients also retain some of the phenotypes similar to multipotent cells 
(Landsberg J et al., 2012) (Lehraiki et al., 2015) (Fallahi‐Sichani et al.,  2017). 
Melanoma cells are transformed from melanocytes which are differentiated from the 
neural crest cells. The neural crest cells are multipotent, transient and migratory cell 
population developed during the neural tube formation. Melanoma cells regain some 
of these features of neural crest cells in order to metastasize and acquire resistance 
from the therapies. Here, I have identified new dedifferentiation marker in melanoma 
cells which could potentially lead to metastasis and resistance to the melanoma 
therapy. 
 
5.1 Identification of novel marker for dedifferentiation and 
resistance in melanoma 
To date, several markers like CD271, CD133 ABCB5 and ALDH have been 
associated with the melanoma dedifferentiation. The dedifferentiated population of 
melanoma cells shows the embryonic phenotype (Boiko et al., 2010) (Monzani et 
al., 2007) (Frank et al., 2005). They are more migratory, invasive and resistant to 
the therapies. Due to ethical limitations in human it is not possible to isolate the 
multipotent neural crest cells and study the link with melanoma pathogenesis.   
The reprogramming of somatic cells using Yamanaka factors provides a new 
approach to study the role of dedifferentiation in cancer cells. Besides, this technique 
opens a new insight in the study of developmental biology by subsiding the ethical 
issues (of using human embryonic stem cells). Previously in our lab, human induced 
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pluripotent stem cells (HiPSCs) were generated and differentiated into neural crest 
cells under controlled conditions. The neural crest cells were identified using two 
different cell surface markers (CD271 and HNK1) (Larribere and Utikal, 2014) 
(Larribere et al., 2015).  
On the other hand, melanoma cell lines were treated with a high dose of BRAF-
inhibitor for a period of 72hours (Figure 4A). This process helped in the selection of 
most resistant and dedifferentiated cell population as the inhibitor can easily 
eliminate the normal tumour cells at this drug concentration (Supplementary Figure 
1) but not the dedifferentiated population. This was also shown in the gene profiling 
data where the neural crest cells clustered together with the vemurafenib-treated 
cells (Figure 4B). This shows that the cell survived after vemurafenib treatment was 
more dedifferentiated than the non-treated or DMSO-treated human melanoma cells. 
This was strongly supported by another finding where it was shown that the 
pluripotency or multipotency markers (LIN28, SOX2, DNMT38, TWIST1and 
POU5F1) were upregulated in the dedifferentiated group of cells. In addition, the 
melanocytic or differentiated markers (DCT, MC1R, MITF, TYR, SOX10 and TYRP1) 
were downregulated in the dedifferentiated group of cells (Figure 4C). It is well 
known that the expression of SOX2, LIN28 and POU5F1 has been implicated in 
dedifferentiation of pancreatic cancer cells, Müller glia and embryonic stem cells 
respectively (Herreros-Villanueva et al., 2013) (Ramachandran et al., 2010) (Niwa 
et al., 2000). Indeed the melanocyte differentiation from neural crest cells requires 
the expression of SOX10 and its downstream gene MITF, DCT, TYR and TYRP1. 
Interestingly, TWIST1 is another gene associated during embryonic development. It 
is upregulated in many cancers and promotes metastasis through epithelial to 
mesenchymal transition (EMT) (Yang et al., 2006). Neural crest cells are migratory 
in nature and express TWIST 1 during entire migratory pjase (Vincentz et al.,  2013). 
Furthermore, the findings show that AXL expression was upregulated in the 
vemurafenib-treated cells which are in accordance with the earlier findings where it 
was described that high AXL and low MITF expression is an early indication of drug 
resistance in BRAF and NRAS mutated cell lines (Müller et al., 2014). Contrastingly, 
many reports suggest an elevated level of MITF in drug resistant melanoma cells 
(Johannessen et al., 2013) (Van Allen et al., 2014). This discrepancy could arise 
due to the difference in the experimental procedures. As I have used BRAF inhibitor 
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PLX4032 (vemurafenib) and not PLX4720. Additionally, the difference of drug 
concentration for the treatment in this study could also affect the end results. 
Inhibitor of differentiation (Id) proteins is expressed in stem cells and maintains the 
stemness by inhibiting the differentiation. In Xenopus embryo, Id3 was shown as an 
essential gene for the proliferation and survival of the neural crest cells (Kee and 
Bronner-Fraser et al., 2005). It has been described to play a quintessential role in 
cancer-initiating cells and drug resistance. This was reflected in the result as well 
where Id1, Id2 and Id3 expression were upregulated in vemurafenib treated cells. Id1 
and Id2 expression have been well studied in melanoma progression and associated 
with the suppression of tumour suppressor genes. Here, the expression of Id3 was 
found to be elevated in the dedifferentiated cells. In my results, I also demonstrated 
the elevated mRNA expression of Id3 in BRAF mutated cell lines (Skmel 28, HT144, 
C32, A375 and WM266-4) after treatment with high dose of vemurafenib. 
Remarkably, the upregulation of Id3 initiates as early as 6 hours after treatment and 
retained after 24hours, 48hours and 72 hours of vemurafenib treatment. Although 
HT144 cell line does not show significant upregulation of Id3 after 72 hours of 
vemurafenib treatment (Figure 4D). This could be because of another resistance 
mechanism involved in this cell line and further investigation is required. This was 
also true for the NRAS mutated cell lines as the Id3 expression increases after 
treatment with the MEK-inhibitor (Trametinib). Formerly, Id3 role in drug resistance 
has been well documented in colon cancer and Non-small cell lung cancer (O'Brien 
et al., 2012) (Castañon et al., 2013). These findings suggest that Id3 expression is 
higher in dedifferentiated melanoma cells and upregulated during adaptive 
resistance. 
 
5.2 Id3 expression mediates migration in melanoma cells 
Id proteins are highly expressed during development but usually found to be low or 
downregulated in terminally differentiated cells. Although their expression in several 
cancer types is dysregulated and supports the tumour cells in proliferation and 
metastasis. For example in hepatocellular cancer Id1 expression is upregulated 
compared to the normal liver cells (Sharma et al., 2016). Similarly, in melanoma 
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cells, Id1 is expressed in the tumour cells but melanocytes do not show any 
expression of Id1 (Straume and Akslen, 2005). Id2 and Id3 expression was variable 
in melanoma cell lines but very low or not expressed in human melanocytes (DiVito 
et al., 2014). Tumour suppressor genes are more often inactivated in cancer, Id1 
transcriptionally inactivates p16INK4a in melanoma whereas Id2 suppresses Rb 
protein in neuroblastoma (Polsky et al., 2001) (Lasorella et al., 2000). In this study, 
it was demonstrated that both at mRNA and protein level Id1 and Id3 expression was 
elevated in most of the human melanoma cell lines compared to the normal human 
melanocytes (NHM). In addition, Id1 and Id3 expression in dermal nevus, primary 
and metastatic melanoma patient samples were found (Figure 5 and 6). However, 
their expression in dermal nevus could indicate that Id1 and Id3 are essential during 
the early transformation of melanocyte to melanoma. To date not enough data has 
been published which explains the mechanism of Id3 in melanoma progression. I 
performed functional experiments to study the role of Id3 in melanoma pathogenesis.  
Melanoma cell lines (A375, Skmel 28, HT144, Skmel147 and MeWo) upon knocking 
down Id3 using shRNA do not show any effect on proliferation (Figure 8). This result 
was further confirmed by cell cycle analysis where I didn’t see any difference in the 
percentage of cells in the different phase of cell cycle (Figure 9). Also, WM266-4 cell 
lines displayed no alteration in proliferation or cell cycle phases upon overexpression 
of Id3 (Figure 11C and 12). Taken together these results suggest that Id3 alone is 
not essential for proliferation and cell cycle in melanoma cell lines. The probable 
explanation could be that Id1 expression in Id3 knockdown cell lines compensate for 
the loss of Id3 since they share 69% homology (Supplementary Figure 5). 
However, melanoma cell lines (A375, Skmel 28 and Skmel 147) showed significantly 
reduced cellular migration upon knocking down Id3 using shRNA (Figure 10). In 
accordance, a significant increase in cellular migration was observed in WM266-4 
cell line on ectopic expression of Id3 (Figure 11 D, E). These results indicate that Id3 
expression in melanoma cell lines is essential for the cellular migration.   
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5.3 Id3 confers dedifferentiation in melanoma cells by regulating 
SOX10 and MITF expression 
Dedifferentiating cells are more migratory in nature compared to the terminally 
differentiated cells. Here, it was shown that melanoma cells upon Id3 knockdown 
migrate slower compared to the melanoma cell line with Id3. Several factors are 
involved in melanoma migration and to analyse the mechanism behind melanoma 
migration involving Id3, a large set of melanoma associated genes were screened.  
Interestingly, in this screening, it was identified that SOX10 gene which was 
inversely correlated with Id3 expression. Furthermore, MITF, downstream target of 
SOX10, was also inversely correlated to Id3 in melanoma.  MITF transcription factor 
is a master regulator of melanogenesis which directly controls the activation of 
important enzymes like DCT, TYR and TYRP1 (Bondurand et al., 2000).  
In the panel of human melanoma cell lines, it was shown that the endogenous level 
of Id3 expression is inversely correlated to SOX10 and MITF. This result was further 
confirmed in the Id3 knockdown and overexpressing cell lines. Three out of five cell 
lines (A375, HT144 and MeWo) showed a significant increase in the SOX10 
expression after Id3 Knockdown (Figure 13A). Conversely, WM266-4 cell line after 
Id3 overexpression displayed almost 50% reduction in SOX10 expression (Figure 
13C). Since MITF has SOX10 binding sites on its promoter sites, I also checked the 
expression of MITF in Id3 knockdown cell lines. Here it was found that MITF 
expression was upregulated in three out of 5 cell lines (Figure 13B). Lastly, the 
inverse correlation of Id3 with SOX10 and MITF was confirmed using the in silico 
data analyses of RNA expression from metastatic melanoma patients (Figure 13E). 
As discussed earlier that MITF is required for the differentiation of melanocytes 
whereas Id3 is the inhibitor of differentiation, my result suggests that in melanoma 
Id3 stops the differentiation by downregulating MITF and SOX10 expression.  
Id3 lacks the basic domain in its structure and it cannot bind directly to the DNA or 
promoter of any gene. However, it binds to other basic helix-loop-helix transcription 
factor and inhibits them from binding to the promoter of the target gene. It is well 
documented that Id3 binds to the E2A (E47/E12) protein and stops it from binding to 
E-box of DNA (Loveys et al., 1996). This protein-protein interaction is known to stop 
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differentiation in cells. Taking this in consideration I again performed some in silico 
search and found that SOX10 has E47 binding sites in its promoter region. 
State-1 
 
 
 
 
 
 
State-2 
 
 
 
 
 
 
 
Figure 17: Id3-mediated regulation of SOX10. State-1 represents when Id3 is 
present in excess inside the nucleus where it binds to the E47 transcription factor 
and inhibits the SOX10 activation by inhibiting E47 from binding to the promoter of 
SOX10. State-2 represents when Id3 is knocked down using shRNA and E47 can 
bind to the promoter of SOX10 which starts the transcription and further activates the 
downstream genes like MITF. 
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No Transcription 
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E47 binds to the E-box motif (5-CANNTG-3) on promoter sequence and using 
another database search it was found that SOX10 promoter has three CANNTG 
motifs (CAGCTG, CACATG and CAAATG) (Figure 14). Taking together these 
observations I propose that Id3 regulates SOX10 expression in melanoma by 
inhibiting E47 from binding to SOX10 promoter and stopping the differentiation. This 
is described by a schematic representation but further research is required to be 
done to formally prove it (Figure 17). 
 
5.4 Id3 in melanoma induces drug resistance to target therapies 
This study presents a direct connection between Id3 expression in melanoma cells 
and resistance to the targeted therapy. The role of Id1 in retaining chemoresistance 
has been well documented before but to our understanding, Id3 role in resistance to 
melanoma target therapy has never been explored. In my results, it was presented 
that BRAF mutated cell lines (A375, Skmel 28 and HT144) are more sensitive to the 
vemurafenib after knocking down Id3 gene (Figure 15A). Whereas, WM266-4 cell 
lines show more resistance to the vemurafenib treatment after the overexpression of 
Id3 gene (Figure 15B). On the other hand, it was found that NRAS mutated cell line 
SKmel 147 also become more sensitive to the MEK-inhibitor (Trametinib) after 
silencing Id3 gene (Figure 15A).  
This is the first time shown that Id3 gene expression in melanoma cell lines helps in 
maintaining the dedifferentiated state by regulating the expression of SOX10 and 
MITF, the most significant genes for the melanocyte differentiation. Although SOX10 
involvement in resistance to BRAF and MEK inhibitor has been described before. 
Sun et al in 2014 found that after knocking down SOX10 in melanoma cells, EGFR 
and PDGFRB expression were upregulated via Tgf-β and conferred resistance.   
As it was highlighted in the introduction, ABCB5 is the drug efflux transporter and is 
crucial for stem cells maintenance. It is also upregulated in several cancers and 
confers resistance to the therapy. Here, using the GEO data set it was found that 
after stably knocking down ABCB5 in A375, the Id3 expression is significantly 
downregulated compared to the vector control. Whereas, the expression of 
melanocyte differentiation markers i.e. SOX10 and MITF significantly increases after 
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ABCB5 suppression (Supplementary Figure 6) (Wilson et al., 2014). These data 
are in agreement with the findings where it was shown that Id3 is upregulated upon 
treatment with BRAF or MEK inhibitors and inversely correlated with the expression 
of SOX10 and MITF. 
In conclusion, this study reveals that Id3 expression in melanoma is crucial for the 
dedifferentiation which is responsible for the resistance to the targeted therapy like 
BRAF and MEK inhibitors. In addition, it was found that Id3 also regulates SOX10 
and MITF expression (potentially via E47) to keep the cells in the more 
dedifferentiated state. 
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6. Summary 
Melanoma is the deadliest form of skin cancer which is transformed from the 
melanocytes. Sunburn is one of the leading causes of melanoma. Patients acquire 
various mutations during melanoma pathogenesis which are responsible for the 
tumour progression, metastasis and invasion. Additionally, a subpopulation of 
melanoma cells is dedifferentiated due to the recapitulation of expression pattern 
also found in neural crest cells. Despite several targeted and immunotherapies have 
been approved for the treatment of metastatic melanoma, the gain of resistance 
reduces the efficiency of these drugs. A number of reports suggest the role of 
dedifferentiation in resistance to the therapies but the exact mechanism behind this 
is poorly understood. Therefore, in this study, a new protein was identified which 
plays role in dedifferentiation and resistance in melanoma cells.  
In this project, it was shown that Id3 expression is upregulated in melanoma cells 
compared to the human melanocytes. Also, it was found that Id3 expression is 
higher in primary and metastatic melanoma patient samples as well as in dermal 
melanocytic nevus cells. By means of gain and loss of function studies, it was shown 
that Id3 alone does not alter the proliferation or cell cycle in melanoma cells. 
However, Id3 expression in melanoma cells promotes cellular migration. On 
screening a large set of melanoma associated genes it was revealed that Id3 
expression is inversely proportional with the melanocyte differentiation marker gene-
SOX10 and MITF. 
It was also demonstrated that Id3 expression is upregulated in the BRAF and NRAS 
mutated cell lines upon treatment with vemurafenib and trametinib respectively. Also, 
from the expression analysis, it was shown that higher Id3 expressing cell lines after 
treatment with inhibitors display dedifferentiated phenotype. Further, I confirmed the 
role of Id3 expression in vemurafenib or trametinib resistance by showing that after 
knocking down or overexpressing Id3 in melanoma cell line sensitizes or confer 
resistant respectively to the treatments. These findings highlight the importance of 
Id3 in melanoma resistance against targeted therapy and inhibition of Id3 clinically in 
metastatic melanoma patients could increase the efficacy of the current treatment.
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8. Appendix: 
 
 
 
A.  
 
 
 
   
   
   
B. 
 
 
 
 
 
 
 
Supplementary Figure 1: Efficacy of vemurafenib treatment. A. Curve represents 
the viability of BRAF mutated melanoma cell lines (A375, Skmel28 and WM266-4) 
and BRAF wild type cell line (Skmel 23) after vemurafenib treatment (0- 10 µM) after 
72h. B. Graph represents the percentage of cells survived after 72h of treatment with 
vemurafenib (1µM). Skmel 23 was used as a negative control. The cell viability 
results shown here are mean of +SD of biological replicates. 
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Supplementary Figure 2: Id3 expression is upregulated during adaptive 
resistance. Graph represents the mRNA expression of Id3 in NRAS mutated cell 
lines (Skmel 30, Skmel 103 and Skmel 147 after treatment with Trametinib (3µM or 
1µM). 18s was used as an endogenous expression control and DMSO treated cells 
were used as reference sample. The qPCR results shown here are mean of + SD of 
biological triplicates. *P<0.05, **P<0.01, ***P<0.001 and ns = not significant.  
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Supplementary Figure 3:  Id3 expression is upregulated during adaptive 
resistance. Id3 mRNA expression in BRAF mutated melanoma cell lines (A375, C32 
and Skmel 28) after 6 hours and 72 hours of treatment with BRAF or MEK inhibitor 
alone or in combination. 18s was used as an endogenous expression control and 
DMSO treated cells were used as reference sample. The qPCR results shown here 
are mean of + SD of biological triplicates. *P<0.05, **P<0.01, ***P<0.001 and ns = 
not significant.  
Appendix 
 
 
  100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4: Id3, SOX10 and MITF protein expression.  Protein 
expression of Id3, SOX10 and MITF in NHM and human melanoma cell lines. 
GAPDH was used as a loading control. 
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Supplementary Figure 5: Unaffected Id1 expression in Id3 knockdown cell 
lines. Protein expression of Id1 in melanoma cell lines with Id3 knockdown and 
control cell lines. GAPDH was used as loading control. 
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Supplementary Figure 6: Melanocyte differentiation marker is upregulated in 
drug sensitive cells. Dataset used was from GSE38290. mRNA expression of Id3, 
SOX10 and MITF in A375 cell line after knocking down ABCB5 gene. The results are 
shown as mean + SD of technical triplicates. *P<0.05, **P<0.01, ***P<0.001 and ns 
= not significant.  
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